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ABSTRACT
Extracellular matrix (ECM) is a dynamic and complex environment characterized
by biophysical, mechanical and biochemical properties specific for each tissue. Cells
constantly experience dynamic mechanical loadings that include compression, shear,
tension, hydrostatic pressure, and interstitial fluid flow. Through the process of mechanochemical conversion, mechanical stimulation activates intracellular biochemical signaling
that affects many aspects of cell behavior including cell proliferation and differentiation,
as well as ECM deposition and organization during development, wound healing, and
pathological diseases. Despite significant advances in understanding the dynamic
relationship between mechanical forces and matrix remodeling, many of the unique
mechanisms and associated responses to various physical stimuli remain to be elucidated.
Fibrosis is a complex disease predominantly characterized by excessive and
abnormal fibrous ECM deposition that leads to the failure of various organs: lung, liver,
kidney and skin. During the normal wound healing process, injured tissue progresses
through phases of hemostasis, acute inflammation, granulation tissue/fibroproliferative,
matrix formation, and remodeling. Collectively, the fibro-proliferative stage terminates
with the restoration of ECM homeostasis and the disappearance of myofibroblasts,
probably through apoptosis. However, the chronic presence of diverse injuries,
commonly involving the abnormal persistence of several profibrotic cytokines results in
sustained myofibroblast activation, excessive ECM deposition, scar formation, and organ
failure. Specifically, transforming growth factor-β (TGF-β) is a master switch that
activates critical downstream molecules in the progression of fibrotic disease. Although
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various strategies designed to interfere with TGF-β expression, receptor binding, and
signal transduction have been studied, a clinically safe and effective therapy has not yet
been developed.
The superficial layer of the lamina propria (SLLP) in the human vocal folds
experiences a unique mechanical microenvironment of high frequency vibration during
voice production. The presence of macrophages/myofibroblasts in the SLLP of healthy
patients suggests that the mechanical stresses imposed during routine speech result in
repetitive microtrauma, which is generally repaired without permanent alterations in
vocal fold matrix composition or vocal quality. In addition, mechanical forces have
recently been shown to alter the fibrotic phenotype in fibrotic fibroblasts. Therefore, the
objective of this research is to understand the mechanisms regulating fibroblast matrix
metabolism in the SLLP and investigate the potential of vibratory stimulation for
treatment of fibrotic diseases.
First, we characterized the transcriptional and translational changes of human
dermal fibroblasts in response to vibratory stimulation and demonstrated that vibratory
stimulation led to the down-regulation of the TGF-β signaling through reduced
expression of TGF-β receptors and Smad signal transduction molecules and increased
expression of SMAD7, ubiquitin ligases, and SIK1 and SKIL, transcriptional repressors
responsible for signaling inhibition. Second, we then investigated the effects of variable
vibratory regimes defined by varying frequency, amplitude, and duration on the
expression of ECM-related transcripts in human dermal fibroblast and found significant
dose-dependent and temporal changes in mRNA expression levels of HA-related
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molecules and profibrotic cytokines, while type I and III collagen expression was
consistently down-regulated across a broad range of parameters. Finally, we tested the
potential therapeutic efficacy of vibration for reversing the fibrotic phenotype in
scleroderma-derived fibroblasts. These studies showed that vibratory stimulation
significantly reduced the mRNA levels of sclerotic pathogenic targets and collagen
synthesis and accumulation. These studies, therefore, suggest that vibration can be used
as a clinical mechanotherapy for a wide range of fibrotic diseases such as systemic
sclerosis and idiopathic pulmonary fibrosis.
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CHAPTER ONE
INTRODUCTION
1.1. Extracellular Matrix (ECM)
Extracellular matrix (ECM) is a complex, three-dimensional network of
macromolecules that provides structural support and contextual information for cellular
growth, communication, survival, adhesion, migration and differentiation [1–3]. It is
primarily composed of fibrous collagenous proteins that strengthen the matrix and
provide resilience and glycosaminoglycans (GAGs) and proteoglycans that create a
highly hydrated gel resistant to compressive forces [4,5]. Cells receive and respond to
biochemical and mechanical signals originating from the ECM, and in turn, modulate the
ECM through control of matrix assembly. These processes are mediated and regulated
through the interaction between cell surface receptors and adhesive glycoproteins in the
ECM, such as fibronectin, laminin, vitronectin, and thrombospondins. Each of these
glycoproteins has distinct functional domains to bind specific cell surface receptors
including integrins, dystroglycans, and syndecans, as well as collagen-binding domains
for their incorporation within the matrix network [6,7].
Collagen is the most abundant fibrous protein that constitutes the main structural
element of the ECM, provides tensile strength, regulates cell adhesion, supports
chemotaxis and migration, and directs tissue development. Of three major collagen types
I, II and III, collagen type I constitutes nearly 90% of all the collagen in the human body.
Collagens are predominantly produced by fibroblasts that either reside in the stroma or
are recruited to it from neighboring tissues. Collagens, like the majority of secreted
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proteins, are synthesized in the rough endoplasmic reticulum and undergo extensive coand post-translational processing. Like all precursor proteins, collagens are initially
synthesized as longer precursor proteins called preprocollagens. Following removal of
the signal peptide from the preprocollagen precursor, the remaining protein is referred to
as a procollagen (or tropocollagen). Procollagen proteins contain globular pro-domains
that include an additional 150 amino acids at the N-terminus and 250 at the C-terminus,
allowing multiple intrachain disulfide bonds between procollagens and stabilizing
procollagen protein and formation of the triple helical structure. Triple helix structures of
collagens (collagen fibrils) are composed of two identical alpha chains (e.g. α1) and a
different alpha chain (e.g. α2). In addition, collage proteins have a unique amino acid
composition consisting of the repeating sequence, Gly-Pro-X or Gly-X-Hyp
(hydroxyproline), where X represents any amino acid except glycine or proline. As much
as 35% of a collagen monomer is composed of glycine with another 20-25% being
proline. Ascorbic acid is required for the collagen synthesis, especially for the synthesis
of hydroxyproline and hydroxylysine [8–10]. Hydroxyproline serves as a stabilizer for
the formation of the collagen triple helix structure and hydroxylysine is necessary for
formation of intermolecular crosslinks in collagen.
After secretion into the extracellular compartment, collagen fibers are further
processed. Proteases remove the globular pro-domains at both the N- and C-termini. The
collagen molecules then polymerize to form collagen fibrils. Accompanying fibril
formation is the oxidation of certain lysine residues by the extracellular enzyme lysyl
oxidase (LOX). Lysyl oxidase (LOX) is an extracellular copper-dependent enzyme that is
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also known as protein-lysine 6-oxidase. LOX acts on lysines and hydroxylysines
producing aldehyde groups, which will eventually form covalent bonds between
tropocollagen molecules, resulting in the formation of highly organized structure with
long and thin diameter rod-like protein. By exerting tension on the matrix, fibroblasts are
able to organize collagen fibrils into sheets and cables and, thus, can dramatically
influence the alignment of collagen fibers.
ECM GAGs are highly anionic polysaccharides secreted into the extracellular
matrix independently or covalently bound to core proteins in the form of proteoglycans.
Hyaluronic acid (HA) is a high molecular weight GAG that contributes to tissue
viscoelasticity. In addition, many GAGs, mostly notably heparin sulfate, electrostatically
bind a wide range of basic growth factors, sequestering them within the matrix and
creating a reservoir for subsequent release during ECM remodeling and wound healing.
Examples include epidermal growth factor (EGF), fibroblast growth factor (FGF) and
other signaling molecules such as WNTs [11]. Following release from the ECM, growth
factors are localized near cell surface receptors and cell adhesion sites [3,12], regulating
ECM architecture and influencing cell behavior controlled by integrin-mediated
signaling.
The vast majority of mammalian cells are anchorage-dependent and require
adhesion to the ECM matrix for survival and phenotypic function. Cell-ECM adhesion is
mediated through transmembrane cell surface receptors that either bind directly to
collagen or bind to multi-domain adhesive glycoproteins that contain both collagenbinding (for incorporation into the matrix) and cell-binding domains. Fibronectin is one
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of the most important adhesive glycoproteins and plays a central role in mediating
mesenchymal cell attachment and migration [2,6,7]. Laminins are a large family of
heterotrimeric ECM glycoproteins composed of α, β, and γ chains [7] that play essential
roles in the nervous system and epithelial basement membranes.
Integrins are one of the most important and widely studied families of cell
adhesion receptors. Integrins are heterodimeric transmembrane receptors formed by noncovalent interactions between α- and β-subunits. At present, 18 α and 8 β subunits have
been identified that form 24 functional receptor combinations. Each integrin subunit
contains a large extracellular ligand-binding domain, a transmembrane helix, and
relatively short (typically 20−70 amino acids) cytoplasmic tail. Integrins bind to
extracellular proteins via a small cell-binding recognition sequence, such as the RGD
motif (found in proteins such as fibronectin, laminin, or vitronectin). Ligand binding
leads to receptor clustering and the recruitment of a variety of cytoplasmic adaptor
proteins such as talin, α-actinin, filamin, vinculin and tensin that bind to both the integrin
cytoplasmic domain and the actin cytoskeleton [13]. The resulting macromolecular
structures, termed focal adhesions, form a physical connection between the ECM and the
intracellular actin cytoskeleton. In addition, myosin-mediated contraction further
promotes actin coupling and allosteric integrin clustering, as well as the recruitment of
other receptors, leading to the formation of signaling complexes for biochemical signal
transduction. These structures help transmit mechanical and chemical signals via
mechanosensitive components at focal adhesions, dependent upon the mechanical forces
they experience as a result of substrate stiffness.
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Although integrins and focal adhesions were initially considered to perform solely
structural/mechanical functions, it is now recognized that they are critical cell signaling
complexes capable of bi-directional signaling. Binding of cytoplasmic proteins to integrin
cytoplasmic tails can trigger a change in integrin affinity for extracellular ligand (insideout signaling/activation). The best example of this is activation of the platelet αIIbβ3
integrin, leading to increased fibrinogen binding affinity, in response to intracellular
signaling initiated by soluble molecules released in response to vascular injury. Integrins
also participate in outside-in signaling initiated by ligand binding. In addition to
numerous structural proteins, focal adhesion formation also involves the recruitment of
cytoplasmic kinases such as focal adhesion kinase (FAK). FAK-dependent activation of
phosphatidylinositol-3´-kinase (PI3K), extracellular signal–regulated kinase (ERK), and
c-Jun NH2-terminal kinase, and Akt/protein kinase B (PKB) are important mechanisms
by which integrin binding influences cell cycle regulation and protects against apoptosis.
A recently recognized and particularly important characteristic of the ECM is that
it is tissue-specific. For example, the ECM in cartilage tissue is enriched in collagen type
II and proteoglycans for resisting compressive stress [14], while the glomerular basement
membrane (GBM) in the kidney is rich in laminin, collagen type IV, and heparan
sulphate proteoglycans that create a selective filtration barrier [15]. Thus, tissue-specific
cells in response to biochemical and biomechanical signals in the local microenvironment
produce an ECM with distinct biochemical composition and biomechanical properties
required to support cellular and tissue function.
1.1.1. ECM Remodeling
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Although it was previously believed that the ECM was a static structure that
changed only in response to growth or injury, it is now recognized that the ECM
experiences complex and dynamic remodeling throughout life. [16]. Thus, precise
orchestration of the ECM remodeling process is crucial to the maintenance of normal
function [17,18]. Careful balance between matrix synthesis and enzymatic degradation
regulated by growth factors, cytokines and mechanical stimulation is important for ECM
remodeling. Specifically, ECM degradation is controlled by various enzymes, including
heparanase, cathepsins, hyaluronidases, matriptases, various serine and threonine
proteases [19], the large superfamily of metzincins, which includes ADAMs (a
disintegrin and metalloproteinases), ADAMTSs (ADAMs with thrombospondin motifs),
and matrix metalloproteases (MMPs) [20,21]. These enzymes regulate matrix
components of the basement membrane as well as proteins and proteoglycans of
connective tissues. As noted above, ECM degradation also liberates sequestered growth
factors, providing a mechanism for coupling their activity to matrix turnover [22].
1.1.2. Regulation of Matrix Remodeling
1.1.2.1. Growth Factors and Cytokines
ECM remodeling is controlled by wide variety of different growth factors and
cytokines, including TGF-β, PDGF, bFGF, EGF, VEGF, TNFα and interleukins (IL)
[23]. TGF-βs have a wide spectrum of activities, regulating cell proliferation and
differentiation as well as synthesis of many ECM components. TGF-β1 induces
monocytes and macrophages to synthesize a number of cytokines such as IL-1β, TNF-α
and TGF-β1 itself [25,26]. These cytokines affect both fibroblasts and inflammatory cells
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to promote the production of new matrix proteins such as collagens I, III, and V,
fibronectin, proteoglycans and other ECM components [40]. In addition, PDGF induces
fibroblast and smooth muscle cell migration and proliferation and stimulates the
activation of macrophages [48-53], resulting in increased procollagen synthesis,
collagenase activation and fibronectin gene expression [54-56]. Fibroblast Growth
Factors (FGFs) are key growth factors involved in angiogenesis, directing endothelial cell
migration, proliferation, and plasminogen activator synthesis [52,64-65]. FGFs have been
shown to accelerate granulation tissue formation, increase fibroblast proliferation and
collagen accumulation, and enhance vascularization [69].
Although many cytokines play important roles in matrix remodeling, TGF-β1 has
clearly been identified as the prototypical ‘profibrotic’ cytokine. Accumulated evidence
has demonstrated that TGF-β1 promotes myofibroblast differentiation and increases
collagen synthesis and accumulation that ultimately leads to fibrosis of many organs [24–
26]. TGF-β is also known to negatively regulate the production of MMP1 and MMP7
[27,28], but induce TIMP1 expression [29]. As noted above, the matrix metalloproteinase
(MMP) family plays a pivotal in the ECM remodeling, collagenous proteins in particular.
Specifically, the down-regulation of MMP1 (a.k.a collagenase-1) is involved in fibrotic
diseases characterized by exaggerated ECM synthesis [27,28,30]. Increased levels of
TIMP-1 as an inhibitor of many active MMPs has also been observed in fibrotic diseases
[27,29]. In addition to its direct profibrotic activity, TGF-β1 also indirectly promotes
fibrosis through the downstream cytokines CTGF and EDN1. Numerous studies have
shown that TGF-β1 is a potent inducer of CTGF expression [31] and CTGF functions as
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a downstream mediator of specific TGF-β1 actions on connective tissue cells, where it
stimulates cell proliferation and ECM synthesis. CTGF has been implicated as a key
regulatory target in complex biological and pathological processes particularly involving
connective tissue formation in wound repair or fibrotic disorders [32,33]. Endothelin 1
(EDN1) is also a downstream mediator of the profibrotic action of TGF-β in the context
of fibrotic diseases; increased EDN1 expression by fibroblasts is a hallmark of fibrotic
disease and it is known to act synergistically with TGF-β [34,35].
1.1.2.2. Mechanical Microenvironment
All cells in multicellular organisms are exposed to mechanical forces of varying
magnitude that play an integral role in regulating cell behaviors such as spreading,
migration, proliferation and differentiation. Cells sense the mechanical microenvironment
via transmembrane molecules and exhibit different mechano-responsive behaviors,
depending upon the mechanical loading types and properties of the ECM. One important
characteristic of the mechanical microenvironment that cells experience is matrix
stiffness, which ranges from 50 Pa (e.g. blood fluid or mucus), 1~2 kPa (e.g. brain), 2-5
kPa (e.g. lung), 5-6 kPa (e.g. skin), 12~13 kPa (e.g. smooth muscle), 1~3 MPa (e.g.
cartilage) and up to 1~20 GPa (e.g. bone) [16][36]. As described earlier, cells detect the
stiffness of the microenvironment by pulling on the ECM and such processes are
dependent on ECM adhesions that act as a bridge to transmit force between the ECM and
the cellular cytoskeleton, in which myosin-based contractility acts as a primary regulator
of cellular contractile forces.
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While TGF-β increases matrix deposition and stiffness, matrix stiffness is also
crucial to promote the expression of various ECM proteins and has been widely studied
using collagen constructs with defined matrix stiffness [37–40]. Elevated expression of
collagen type 1, 2, 3 and 6, fibronectin and α-actin were observed and fibroblasts
developed enlarged actin microfilament bundles and organized fibronectin into
extracellular fibrils during culture in stressed collagen gels [41,42]. Interestingly, the
inhibitors of matrix metalloproteinases such as TIMP1 and TIMP3 were significantly
induced in response to increased substrate stiffness [38]. Meanwhile, fibroblasts cultured
in freely floating, relaxed collagen lattices exhibited decreased collagen synthesis [43],
but increased synthesis and activation of matrix metalloproteinase (MMP)-1 [44][45].
These studies demonstrate that matrix rigidity affects not only the synthesis and
production of ECM components but also other targets associated with fibrotic diseases
including the deposition and organization of these components.
A second important characteristic of the mechanical microenvironment that
influences matrix synthesis is the exposure of cells to applied external loads/forces. For
instance, fibroblasts in ligament, chondrocytes in cartilage, and endothelial cells (EC) in
vascular tissues experience tension, compression and shear stress, respectively, regulating
their matrix transcription and production [50–53]. Mechanical stretch plays an active role
in many physiological processes such as muscle contraction. It has been demonstrated
that the stretching forces stimulated cells in many engineered tissues (e.g. muscle,
ligament, tendon and vasculature) to enhance their organization, strength and
functionality [50, 54]. Smooth muscle cells (SMCs) have shown directed cell alignment
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and migration in collagen substrates parallel to the direction of mechanical stretch [55],
down-regulated expression of bone-associated genes, and decreased deposition of
calcium [56]. Cyclic stretch promoted myocardial cells to form interconnected and
longitudinally oriented cardiac muscle bundles [57]. Additionally, cardiac cells in fibrin
and fibroblasts in collagen tend to increase collagen synthesis and deposition under cyclic
stretch [58, 59]. Compressive and shear stresses selectively affect certain types of cells
including chondrocytes, mesenchymal stem cells (MSCs) and endothelial cells (ECs).
Dynamic compression greatly increased equilibrium modulus, glycosaminoglycan and
hydroxyproline content of chondrocytes in an agarose hydrogel construct [60]. Dynamic
compression also enhanced production of cartilage matrix by MSCs cultured in HA
hydrogels [53]. ECs in the human vascular system experience shear stress from the
passage of blood fluid through the cardiovascular system, which plays an important role
in regulating vascular matrix composition and function [64, 65]. Collectively, exposure to
physiologically relevant external mechanical stimulation activates signaling pathways to
stimulate tissue-specific matrix expression.
1.2. Wound Healing
The wound healing process is a dynamic and highly regulated process of cellular,
humoral and molecular events involving cell migration, proliferation, and matrix
remodeling [46,47]. Following tissue injury, the first stage of acute wound healing is
dedicated to hemostasis and the formation of a provisional wound matrix, and the
inflammatory process, which is divided into an early phase with neutrophil recruitment
and a late phase with the appearance and transformation of monocytes. The proliferative
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phase involves re-epithelialization of the wound surface, formation of granulation tissue
and the restoration of the vascular network through neovascularization and angiogenesis.
The formation of granulation tissue stops through apoptosis of the cells, then the newly
synthesized ECM components undergo remodeling resulting in the formation of a mature
scar, which is the physiological endpoint of wound repair and directly linked to the extent
of the inflammatory process throughout wound healing.
1.2.1. Hemostasis
The initial injury results in an outflow of blood and lymphatic fluid. Immediately
after injury, blood vessels constrict and the process of initial reparative coagulation is
initiated [48]. Minor injury to the endothelial layer exposes a number of matrix proteins
including type IV collagen, laminin, and Von Willebrand factor (VWF), and in some
situations, fibronectin, whereas more severe injuries exposing the smooth muscle layer or
interstitial ECM will expose fibrillar collagens, elastin, microfibrils, and other ECM
proteins [49]. Although platelets can bind directly to these ECM proteins, interactions
with VWF and fibrinogen are most important for hemostasis [50]. Circulating VWF can
be bound directly by platelets or can bind to exposed collagen fibers. Especially when
activated by collagen, GPVI, a receptor for fibrillar collagens provides stimulatory
signaling that triggers various platelet responses such as activation of αIIbβ3 integrin,
granule release, and cytoskeletal rearrangements. Platelets bind and aggregate together
through two VWF binding receptors GPIb-V-IX complex and the platelet-specific
integrin, αIIbβ3 that bind to the binding site, KQGADV sequence near the carboxyl
terminus of the γ chain of fibrinogen [49]. Once the platelets are activated and engaged
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by ligand, GPIb-V-IX and by soluble by-products of the clotting cascade including
thrombin that cleaves circulating fibrinogen to fibrin and activates Factor XIIIa, causes
“inside-out” activation of αIIbβ3. Subsequently, the interaction with other ECM ligands
deposited on the surface of the thrombus further enhances platelet aggregation and
formation of an occlusive thrombus, contributing to the mechanical stability of the fibrin
network and also undergoing degranulation to release cytokines and growth factors. After
an initial period of vasoconstriction, vasoactive amines released from the platelets and
mast cells cause surrounding vessels to become leaky, thus allowing a massive influx of
inflammatory cells and other blood cells required into the wound area. The final product
of the coagulation process, the fibrin clot, is not only important for hemostasis, but also
provides a provisional matrix for cell migration in the subsequent phases of the
inflammatory and proliferative phases.
1.2.2. Inflammatory Phase
As described earlier in the introduction, the inflammatory phase of the wound
healing cascade is initiated and activated during the hemostasis and coagulation phase.
Overall inflammatory events are roughly divided into an early phase with neutrophil
recruitment and a late phase with the appearance of monocytes and their transformation
into tissue macrophages. Due to the response of the activated complement pathway,
degranulated platelets, and by-products of bacterial degradation, neutrophils are recruited
to the injury site through chemotaxis. They perform phagocytosis and secrete high levels
of proteases to kill local bacteria and degrade necrotic tissue [51]. Neutrophils also
secrete pro-inflammatory cytokines and chemokines that are responsible for the
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recruitment and activation of additional polymorphonuclear leucocytes, macrophages,
mast cells, and T cells Th1 and Th2 lymphocytes that are involved in the inflammatory
phase through the release of mediators such as tumor necrosis factor (TNF)-α, IL-1β and
IL-4, IL-5, IL-6, IL-8, IL-10, and growth factors including transforming growth factor
(TGF)-α, TGF-β, platelet-derived growth factor (PDGF), vascular endothelial growth
factor (VEGF), and basic fibroblast growth factor (bFGF).
Macrophages play an integral role in not only supporting the clearance process by
performing phagocytosis of pathogens and cell debris [52,53], but also initiating the
proliferative phase through the synthesis of numerous mediators and growth factors that
promote cell proliferation and the synthesis of ECM molecules by resident cells [54].
Although the resting, non-activated macrophages produce only low levels of proinflammatory mediators, once exposed to pro-inflammatory cytokines including
interferons, lipopolysaccharide (LPS) or other microbial products (such as bacterialderived unmethylated CpG-DNA), or damage-associated molecular patterns (DAMPs;
such as heat-shock proteins, high mobility group box proteins (HMGB1), and molecular
fragments of the extracellular matrix that are generated following tissue injury),
macrophages develop a pro-inflammatory, classically activated phenotype (M1).
Following activation, macrophages themselves produce a large number of mediators and
cytokines including interleukin-1, interleukin-6, interleukin-12, TNFα, and inducible
nitric oxide synthase (iNOS) [26,55]. Recent studies of macrophages derived from skin
wounds as well as sponges implanted subcutaneously in mice demonstrate that
macrophages exhibit multiple phenotypes that change during the inflammatory phase of

13

the wound healing process [56]. These studies suggest that M1-like macrophages are
common in the early phases of repair, while alternatively-activated (M2) macrophages,
with less pro-inflammatory cytokines and elevated markers of alternative activation,
including CD206 and arginase 1 (Arg1), are common in later stages of repair [57–59].
Thus, the transition from a pro-inflammatory to a pro-healing phenotype in macrophages
is an essential process in normal wound healing. In addition, T lymphocyte that appear in
the wound bed in the late inflammatory phase also regulate the phenotype shifts from
pro-inflammatory macrophages to macrophages with anti-inflammatory/proangiogenic
cytokine activities, suppressing inflammatory responses and inducing neovascularisation
and fibroblast and epithelial cell proliferation, thereby leading to the transition from
inflammation to repair [53]. The inflammatory response to injury is therefore essential for
supplying growth factors and cytokine signals that are important for cell recruitment and
activation, which are also crucial for the subsequent repair mechanisms in adult mammals
[51,60].
1.2.3. Proliferative Phase
The main characteristics of the proliferative phase are re-epithelialization,
replacement of the provisional matrix with newly formed granulation tissue, and
restoration of the vascular network [61,62]. A variety of cytokines and growth factors
released by inflammatory cells stimulate cells such as fibroblasts, endothelial cells, and
keratinocytes to promote cellular recruitment and proliferation, produce ECM proteins
and glycoproteins, and initiate angiogenesis. Fibroblasts secrete bFGF, TGF-β, PDGF,
insulin-like growth factor 1 (IGF-1), and keratinocyte growth factor (KGF). Endothelial
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cells produce vascular endothelial growth factor (VEGF), bFGF, and PDGF.
Keratinocytes also synthesize TGF-β, TGF-α, and KGF. VEGF and FGF2 stimulate
blood vessel formation and re-epithelialization. PDGF and TGF-β play a particularly
important role in stimulating fibroblast proliferation and migration into the provisional
matrix.
Under the control of regulating cytokines like IFN-γ and TGF-β, fibroblasts
initially synthesize a matrix rich in glycosaminoglycans (GAGs) and glycoproteins
including fibronectin and tenascin [61–63] that serves as a transitional matrix to support
subsequent collagen deposition and assembly. It is characterized by a high density of
fibroblasts, granulocytes, macrophages, capillaries and loosely organized collagen fibrils.
It serves to close tissue gaps and provide temporary mechanical stabilization of the
wound. Growth factors released by macrophages and other cells that are recruited into the
wound area further facilitate the migration of keratinocytes, fibroblasts and endothelial
cells and the synthesis of new collagens, the subtypes I and III. Early in normal wound
healing, type III collagen predominates but is later replaced by type I collagen. The fibril
assembly, organization, and degradation are mediated by the binding of small leucinerich proteoglycans (SLRPs) to different types of collagens through the covalent links of
glycosaminoglycan (GAG) side chains [64,65]. The interaction of SLRPs with collagens
has been shown to enhance fibril stability and to protect fibrils from proteolytic cleavage
by various collagenases [66]. Especially, decorin is known to associate with collagen
fibrils by binding to collagen type I, II, III, IV, VI, and XIV in all connective tissues. The
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GAG chain of decorin also binds tenascin-X and mediates its interaction with collagen
fibrils, thereby contributing to ECM integrity [67].
Angiogenesis is a complex cascade of molecular events in the wound site to
restore vascular circulation and deliver oxygen and nutrients to support tissue repair
[68,69]. The process is initiated by growth factors, such as VEGF, PDGF, bFGF and the
serine protease thrombin. The first step in new vessel formation is the binding of growth
factors to their receptors on the endothelial cells of existing vessels, thereby activating
intracellular signaling cascades. The activated endothelial cells secrete proteolytic
enzymes that degrade the basal lamina by secretion and activation of MMPs. Endothelial
cells then migrate and proliferate into the provisional wound matrix, a process known as
‘sprouting’ [70]. The sprouts form small tubular canals that interconnect to others
forming a neovessel loop. Thereafter, the new vessels differentiate into arteries and
venules and mature by further stabilization of their vessel wall via the recruitment of
pericytes and smooth muscle cells.
Finally, the synthesis of collagen increases throughout the wound while adjusting
a balance between synthesis and degradation of the ECM [63], and the number of
maturing fibroblasts is subsequently reduced by myofibroblast differentiation, downregulated along with decreased vascularity, and terminated by c-Myc-induced cell
apoptosis [71–73]. Several in vitro studies suggest that fibroblast apoptosis is mediated
by the cell surface interactions of Fas (CD95) with its ligand, FasL (CD95L) on the cell
membrane. Fas is a cell surface transmembrane receptor of the tumor necrosis factor
receptor family that activates an intrinsic apoptotic suicide program in cells upon binding
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its ligand FasL. Fas/FasL binding initiates the apoptotic signaling pathway through cMyc that ultimately leads to the activation of caspase proteases and the apoptosis of
myofibroblasts, restoring cell density to pre-injury levels [74,75].
1.2.4. Remodeling Phase
As the last phase of wound healing, the remodeling phase is responsible for the
development of new epithelium and final scar tissue formation. Since 1971,
myofibroblasts, after discovery by Gabbiani et al. in the granulation tissue, have been
identified to play an important role in wound contraction and scar formation during the
wound healing process [76,77]. During the remodeling phase, myofibroblasts are
responsible for massive synthesis and production of ECM proteins, including collagen
types I-VI and XVIII, glycoproteins, and proteoglycans and other matrix molecules such
as laminin, thrombospondin, glycosaminoglycans (GAGs), hyaluronic acid (HA), and
heparan sulfuate (HS), as well as matrix-modifying proteins such as matrix
metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs).
Meanwhile, the components of the wound ECM undergo certain changes; collagen type
III, the major component of the granulation tissue, is slowly degraded and replaced with
collagen type I. The collagen fibres are reorganized in an equilibrium-producing fashion
and are stabilized by increased covalent cross-linking of collagen molecules by the
enzyme lysyl oxidase (LOX), which is secreted into the ECM by fibroblasts [52].
Eventually, the initially disorganized collagen bundles are decreased, the newly oriented
and cross-linked collagen matrices are increased over time.
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In addition to producing matrix components, myofibroblasts also generate
contractile forces that ultimately lead to re-organization of collagen matrix and wound
closure [78]. Initially, cell traction forces (CTFs) generated by fibroblasts lead to the
migration of more fibroblasts from the surrounding dermis and subcutaneous tissues into
the wound [79]. As contraction proceeds and resistance increases, fibroblasts are
differentiated into myofibroblasts that express the contractile proteins, α-smooth muscle
actin (α-SMA) [80]. The bundles of cytoplasmic microfilaments are associated with
contractile proteins including non-muscle myosin that provide large contraction forces
and lead to re-organization of collagen matrix [76,81,82].
The maturation of granulation tissue also involves a reduction in the number of
capillaries as small vessels are aggregated into larger ones and collagens further
accumulate, accompanied by a decrease in the amount of GAGs and proteoglycans.
Moreover, as new blood vessels enter the wound repair area and the oxygen tension
returns to a normal level, oxygen binds to hypoxia-inducible factor (HIF), a highly
conserved transcription factor that controls the expression of numerous angiogenic
factors, and blocks its activity leading to a decreased synthesis of VEGF [69,83].
Furthermore, as the angiogenic process diminishes, the wound blood flow declines and
the wound metabolic activity slowly returns to homeostatic levels.
1.3. Fibrosis
Fibrosis describes a complex, diverse group of chronic pathological diseases [84]
characterized by the excessive accumulation of fibrous connective tissue such as
collagens and fibronectins and eventually results in permanent scarring, ultimately organ
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malfunction and death [16,85,86]. Fibrosis affects nearly every tissue in the body
including the lung, skin, heart, kidney and it is estimated that 45% of deaths in the United
States can now be attributed to some type of chronic fibrotic disease [87]. There are many
triggers that can initiate the progressive fibrotic disease. Examples include inherited
genetic disorders, persistent infections, recurrent exposure to toxins, irritants or smoke,
chronic autoimmune inflammation, minor human leukocyte antigen mismatches in
transplants, myocardial infarction, high serum cholesterol, obesity, and poorly controlled
diabetes and hypertension. Regardless of all of these events, a common feature in all
fibrotic disorders is the activation of fibroblast to myofibroblasts, which is the key
mechanism in fibrotic pathology.
Myofibroblasts are rarely found in healthy human physiology, however they
become vastly increased after injury and play a critical role in the wound healing
response. The myofibroblast phenotype is defined by the formation of a contractile
apparatus with associated contractile proteins, such as α-smooth muscle actin (α-SMA)
and non-muscle myosin, increased levels of ECM synthesis and secretion, and resistance
to apoptosis [40,88–91]. Myofibroblasts are also well-characterized to differentiate from
resident fibroblasts in vivo and in vitro in response to profibrotic cytokine stimulation.
Many cytokines released by inflammatory cells such as TGF-β1, interleukin (IL)-1β, IL6, IL-13, IL-33, as well as prostaglandins and leukotrienes facilitate the activation of
fibroblasts into myofibroblasts. In turn, fibroblasts produce and secrete cytokines such as
TGFβ1, IL-1β, IL-33, CXC, and CC chemokines, allowing them to assist in the activation
and migration of resident immune cells such as macrophages [51]. Moreover,
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myofibroblasts have been observed to differentiate from various other precursor cells,
including epithelial cells, endothelial cells, pericytes, multipotent monocytes, and
fibrocytes. However, how they lead to differential fibrotic responses in different tissues
remains to be determined [92].
Heart failure, the clinical manifestation of numerous forms of cardiovascular
disease (CVD), is a devastating disorder that causes substantial mortality in the United
States, accounting for nearly 600,000 deaths per year. Nearly all etiologies of heart
disease involve pathological myocardial remodeling characterized by excessive
deposition of ECM proteins by cardiac fibroblasts, which reduces tissue compliance and
accelerates the progression to heart failure [93]. Unlike other organs, the heart has a
limited regenerative capacity after injury, and instead, repair processes involve the
removal of necrotic cardiomyocytes followed by fibrotic scar tissue replacement that acts
to preserve myocardial structural and functional integrity. Cardiac fibroblasts play an
essential role in cardiac wound healing processes consisting of inflammation,
proliferation of non-myocytes, and scar maturation [94]. After an acute myocardial
injury, various pro-inflammatory cytokines and profibrotic factors are upregulated that
lead to increased proliferation of cardiac fibroblasts and ultimately, the phenotypic
transition to the myofibroblasts. During this maturation phase, myofibroblasts produce
elevated amount of collagens and other ECM proteins in order to maintain the structural
integrity and pressure-generating capacity of the heart, because a loss of integrity in the
mechanical strength of the ventricle may lead to myocardial dysfunction. In the advanced
phases of fibrotic scar formation, activated myofibroblasts express contractile proteins
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such as α-SMA, resulting in elevated stiffness of the developing scar tissue. These
processes eventually contribute to pathological cardiac remodeling, leading to altered
ventricular structure and compliance, and a concurrent progression into heart failure [95].
Chronic kidney disease (CKD), an epidemic affecting 10-13% of all adults
worldwide and accounting for about a million deaths per year [96], results in the
widespread tissue scarring leading to complete destruction of kidney parenchyma and
end-stage renal failure (ESRD). Renal fibrosis, the final common manifestation of a wide
variety of CKDs is characterized by glomerulosclerosis, tubulo-interstitial fibrosis,
inflammatory infiltration, and loss of renal parenchyma characterized by tubular atrophy,
capillary loss, and podocyte depletion [97] and gradually develops in response to
prolonged hypertension and diabetic glucose dysregulation [86,98]. Like other fibrotic
diseases, the pathogenesis of renal fibrosis is characterized by an excessive accumulation
and deposition of ECM [99–101]. After the initial injury, the affected kidney tissues
undergo a series of events in an attempt to repair and recover from the damage. Kidney
resident cells are activated to produce pro-inflammatory cytokines, resulting in the
infiltration of inflammatory monocytes/macrophages and T cells to the injured sites.
Depending upon the nature and sites of injury, glomerular or interstitial infiltrating
inflammatory cells become activated, and produce injurious molecules such as reactive
oxygen species, as well as fibrogenic and inflammatory cytokines. These mediators
stimulate glomerular mesangial cells, fibroblasts, and tubular epithelial cells to undergo
myofibroblastic activation or transition and produce a large amount of ECM components.
Continuous, dysregulated deposition of ECM proteins such as type I and type III collagen
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and fibronectin results in fibrous scars and distorts the fine architecture of kidney tissues,
leading to the collapse of renal parenchyma and the loss of kidney function.
Liver fibrosis and its end-stage, cirrhosis, remain a massive health care burden
worldwide [102] . The main causes of liver fibrosis are chronic viral hepatitis B or C
infection, autoimmune and biliary diseases, alcoholic steatohepatitis (ASH) and,
increasingly, nonalcoholic steatohepatitis (NASH), that lead to the replacement of
functional parenchyma with scar tissue and ultimately, severe architectural and vascular
distortion in liver tissue [102]. In addition, the clinical complications of cirrhosis involves
ascites, renal failure, hepatic encephalopathy, and variceal bleeding and liver
transplantation is indicated as the only effective therapy [103]. Based on the central
etiology of fibrogenesis, the activation of tissue fibroblasts into ECM producing
myofibroblasts is also considered as a primary mediator in liver fibrosis. Within the liver,
hepatic stellate cells (HSC) that reside in the subendothelial space of Disse, which
contains a low-density basal membrane–like matrix that is essential for maintaining the
differentiated function of parenchymal cells, are the main effector cells of fibrosis
[104,105]. Quiescent HSCs become activated to a contractile myofibroblast-like matrixsecreting phenotype, and secrete fibrillar collagens. In addition, the altered balance
between matrix synthesis and degradation e.g. increased expression of tissue inhibitors of
metalloproteinases (TIMP) and decreased matrix-degrading MMP activitiy further leads
to progressive deposition of ECM matrix in the space of Disse [106], resulting in the loss
of the normal fenestrations of the endothelial lining, creating impaired metabolic
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exchange between portal venous flow and hepatocytes, eventually resulting in liver
failure [107].
Idiopathic pulmonary fibrosis (IPF) is the most progressive and lethal form of
pulmonary fibrotic diseases, with no proven effective therapy, and with lung
transplantation remaining the only viable intervention in end-stage disease [108,109].
Although the precise mechanisms that drive the development of pulmonary fibrotic
disease remain incompletely understood, aberrant lung fibroblasts, loss of alveolar
epithelial cells, and excessive accumulation of ECM appeared to be responsible for
pulmonary fibrosis [110]. The continuous activation of lung fibroblasts to a synthetic and
contractile myofibroblast phenotype leads to the excessive ECM deposition and
contraction of ECM matrix [111,112]. In addition, several lines of evidence demonstrate
that the loss of normal alveolar epithelial cells that is important for gas exchange and
production of alveolar ECM components and replacement by hyperplastic type II cells or
bronchiolar cuboidal cells contribute to the perpetuation of the fibrotic scarring [113].
Thus, altered lung mesenchymal cells coupled with alveolar epithelial cell injury result in
the destruction of pulmonary architecture.
Hypertrophic scars and keloids result from abnormal wound healing in response
to skin injuries such as surgery, burns, trauma, and inflammation in predisposed
individuals [114,115]. Hypertrophic scars usually occur shortly after injury and may
subside with time, however, leaving behind an unsightly wide gap of thinned dermis in
the wound edges. On the other hand, keloids may infiltrate into surrounding normal
tissue, and manifest over time without a quiescent or regressive phase. Hypertrophic and
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keloid scars begin as the result of prolonged inflammatory and proliferative responses
particularly in the injury to deep dermis. Hypertrophic scar fibroblasts respond normally
to growth factors and demonstrate only a modest increase in collagen production.
Fibroblasts in keloids, however, have different properties than those seen in normal skin
and hypertrophic scars [116–118]. Fibroblasts from keloid scars respond abnormally to
stimulation, show a greater capacity to proliferate and produce high levels of collagen
type I, elastin, fibronectin, and proteoglycan. For example, collagen synthesis is
approximately 20 times as great as that in normal unscarred skin and three times as great
as in hypertrophic scars. Keloid tumors then grow to reach a certain size and may remain
that size indefinitely. Aside from high collagen synthesis and proliferation of fibroblasts
in keloids, keloid-derived fibroblasts also show a high rate of fibronectin biosynthesis
that is as much as four times as high as those of fibroblasts derived from normal scars and
normal dermis. With regards to increased expression of TGF-β and its stimulation of
fibroblast proliferation and migration in wounds, in keloidal tissue, TGF-β is
overproduced and poorly regulated through normal autocrine signaling mechanisms
[118]. Moreover, keloid fibroblasts have greater numbers of growth factor receptors and
respond more intensely to growth factors such as TGF-β and PDGF. Decreased synthesis
of molecules that promote matrix breakdown (e.g., MMPs) and disturbed apoptosis
mechanisms have also been reported in hypertrophic scars and keloids, leading to
uncontrolled, progressive collagen synthesis in wounds. Furthermore, several studies also
indicate that both types of fibrotic scarring can develop from extremely increased
mechanical skin tensions induced by high collagen synthesis and proliferation of
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fibroblasts [115]. Specifically, scars located in certain areas of the body (e.g., sternum,
deltoid, and upper back) frequently become hypertrophic.
Fibrosis is also a major pathological feature of many chronic autoimmune
diseases. For example, scleroderma (systemic sclerosis, SSc) is a connective tissue
disease defined by autoimmunity and inflammation, progressive tissue fibrosis and
widespread vascular disorder [119], affecting over 100,000 individuals in the United
States. Vasculopathy in the larger vessels can manifest as pulmonary arterial
hypertension (PAH) or scleroderma renal crisis (SRC), involving fibrointimal
proliferation of small vessels and vasospastic episodes triggered by cold or stress
(clinically referred to as Raynaud’s phenomenon) and ultimately leads to tissue ischemia.
Moreover, dysregulation of the immune system activates autoantibody production,
aberrant cytokine and chemokine release, and destruction of the innate immune system,
further leading to the activation of fibroblasts and recruitment of progenitor and/or stem
cells from the bone marrow and circulation. Prolonged inflammation and the presence of
local and systemic profibrotic factors facilitate the transdifferentiation of resident
fibroblasts and recruited cells such as pericytes, fibrocytes, endothelial and endothelial
progenitor cells into myofibroblasts, which are responsible for the deposition of large
quantities of ECM components [120]. Progressive replacement of tissue architecture by
ECM components such as collagen and fibronectin results in functional impairment of
affected organs. Ulcerative colitis (UC) and Crohn's disease (CD) are intestinal fibrosis
resulting from chronic inflammation and impairment of intestinal wound healing. In UC,
the involvement of the mucosal and submucosal layers causes a thickening of the
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muscularis mucosae with accumulation of ECM that may contribute to shortening or
stiffening of the colon, whereas in CD, the transmural nature of the inflammatory process
is followed by bowel wall thickening, and eventually formation of stricture and stenosis
[121]. In addition, myelofibrosis (MF) is characterized by a clonal haemopoietic stem cell
proliferation associated with a characteristic stromal pattern, a leuko-erythroblastic blood
film and elevated levels of various inflammatory and pro-angiogenic cytokines [122].
1.3.1. TGF-β Signaling and Fibrotic Diseases
As the key molecules in the activation and progression of fibrotic disorders, the
profibrotic cytokines, transforming growth factor (TGF)-β and connective tissue growth
factor (CTGF) are considered as critical mediators in the fibrotic program, stimulating
massive ECM synthesis and deposition by local fibroblasts/myofibroblasts [24,123–126].
The imbalance between enhanced production and deposition and impaired degradation of
ECM components, primarily collagens results in tissue fibrosis.
TGF-β1 is implicated in a wide range of cell functions, critically regulating tissue
homeostasis and repair, immune and inflammatory responses, ECM deposition, cell
differentiation, and growth [127,128]. In mammals, three structurally similar isoforms of
TGF-β, TGF-β1, 2, and 3 are expressed in a distinct tissue specific manner under control
of different promoters [129,130]. Although the in vitro functions of the three isoforms are
similar, however their in vivo effects are distinct. Loss-of-function experiments in mice
have demonstrated that each TGF-β isoform plays an independent role in embryonic
development highlighting their non-compensated functions. Moreover, although all three
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isoforms are expressed in fibrotic tissues, the development of tissue fibrosis is primarily
attributed to TGF-β1 [131].
Members of the TGF-β superfamily elicit signaling through distinct combinations
of transmembrane type I (TGFβRI) and type II receptors (TGFβRII) [132]. Type I and
type II receptors are serine/threonine kinases that form a heteromeric complex. In
response to ligand binding to type II receptor, a stable complex with type I receptor is
formed allowing its transphosphorylation and thus activation of type I receptor kinases.
Among the seven known mammalian type I receptors termed activin receptor-like kinase
(ALK1-7), ALK5 is expressed on many different cell types and is utilized by TGF-β1 for
signaling [133]. There are additional receptors for TGF-β, including the type III receptors
β-glycan and endoglin that serve as accessory co-receptors and facilitate TGF-β ligand
binding to the type II receptor [134].
The signaling pathway for TGF-β further propagates the signal through
phosphorylation of the Smad proteins [135]. The eight mammalian Smads can be
grouped into three functional classes: the receptor-regulated Smads (R-Smads, Smadl,
Smad2, Smad3, Smad5, and Smad8), the common mediator Smad (Co-Smad, Smad4),
and the inhibitory Smads (I-Smads, Smad6 and Smad7). The R-Smads, Smad2 and
Smad3 are phosphorylated directly by the TGF-β receptor (ALK5) [136]. Subsequently,
the R-Smads form complexes with the Co-Smad, Smad4, and translocate to the nucleus,
where they activate or repress gene transcription depending on their recruitment into
transcriptional complexes of co-activators such as p300, CBP, AP-1, signal protein 1
(SPl) or co-repressors such as c-Ski, SnoN, transforming growth inhibiting factor, or
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Smad nuclear-interacting protein-1 (SNIP1) [137]. The I-Smads serve as negative
regulators: Smad6 and Smad7 antagonize TGF-β signaling by binding to type I receptor
(Smad7) or by competing with activated R-Smads for binding to Co-Smad4 (Smad6)
[138]. Moreover, inhibitory Smads (I-Smads) recruit the E3 ubiquitin-protein ligases
Smurf1 and Smurf2 that target Smad proteins for proteasomal degradation, thereby
terminating Smad-mediated signaling [139,140]. Smad7 expression is also induced by
Smad3 [141], therefore providing auto-inhibitory feedback loop that suppresses TGF-βmediated effects [142].
TGF-βs and their receptors are consistently upregulated and activated in fibrotic
diseases and modulate fibroblast phenotype and function [24,126,143]. Relevant to
fibrosis, TGF-β is rapidly induced, assisting in recruiting neutrophils, macrophages, and
fibroblasts, which in turn release more TGF-β and the elevated expression of TGF-β
receptors results in further activation of receptor-mediated TGF-β signaling transduction
(72, 73). In dermal fibrotic lesions of scleroderma patients, elevated TGF-β levels are
observed at the lesion of scar tissues (74). Furthermore, TGF-β1 stimulation leads to
activation and differentiation of fibroblasts to myofibroblasts, the key effector cells in
fibrotic states [121,143].
In addition, TGF-β signaling has been shown to play an important role in
epithelial-to-mesenchymal transition (EMT) [133,144,145]. While EMT is a normal
physiological process necessary for proper tissue development, the pathologic induction
of EMT is associated with fibrotic diseases [146,147]. TGF-β induces the mesenchymal
transdifferentiation of epithelial cells, resulting in the increased expression of genes
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associated with myofibroblast phenotype, the disruption of cell–cell and cell–matrix
interactions, degradation of the surrounding ECM, and actin reorganization.
In normal wound healing, myofibroblasts are required for tissue repair; however,
in pathologic conditions, activated myofibroblasts become the critical effectors of fibrotic
disorders. To repair, regenerate and restore homeostasis after injury, tissue-resident
fibroblasts are activated and transform into myofibroblasts, contractile cells expressing αSMA, desmin, and myosin bundles. It is well established that the first changes that
fibroblasts undergo during myofibroblastic modulation are the acquisition of contractile
stress fibers composed of cytoplasmic actins and the production of cellular fibronectin
[71]. Under mechanical stress, fibroblasts will differentiate into proto-myofibroblasts,
which form cytoplasmic actin-containing stress fibres that terminate in fibronexus
adhesion complexes [148]. Myofibroblasts sustain the contraction by using the
specialized adhesion complex that allows intracellular actin filaments to bind with
extracellular fibronectin domains, ED-A fibronectin expressed and organized by protomyofibroblasts [78]. As noted above, in the presence of mechanical stress along with the
presence of TGF-β, the differentiation of proto-myofibroblasts into myofibroblasts leads
to more extensively developed stress fibres and large fibronexus adhesion complexes.
Subsequently, this contraction is stabilized and replaced by the deposition of ECM,
collagen in particular, leading to maturation of the ECM microenvironment. During
normal wound healing, myofibroblasts undergo apoptosis after re-epithelialization of the
wound. However, in pathological wound healing and fibrotic diseases, the myofibroblasts
became resistant to programmed cell death, persist in the wound site and lead to tissue
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deformation. The long-term existence and uninterrupted matrix accumulation by
myofibroblasts leads to destruction of normal ECM structure and its replacement with
fibrous tissues, which is particularly evident in many fibrotic events: hypertrophic scars
developing after burn injury and in the fibrotic phase of scleroderma [84,149].
1.3.2. Reversibility of Fibrosis
It is generally considered that once fibrosis has begun, it cannot be reversed due
to the activated myofibroblasts, uncontrolled collagen synthesis, and LOX-mediated
crosslinking of collagen matrices. As described earlier, fibrotic processes are
characterized by an excessive accumulation of collagen with increased levels of
hydroxyallysine-derived cross-links. The occurrence of these cross-links appears to be an
important criterion in assessing the reversibility of fibrosis. In normal skin, levels of
pyridinolines derived from hydroxyallysine aldehyde is very low, however, during the
fibrotic process, increased formation of pyridinoline cross-links is observed [150,151].
Elevated hydroxyallysine cross-linking mediated by LOX has consistently been found in
several human fibrotic disorders, such as hypertrophic scar and liver fibrosis [152–156].
This observation suggests that collagen containing hydroxyallysine cross-links is less
susceptible to proteolytic degradation and therefore the collagen deposition is no longer
reversible.
Recent studies have demonstrated that fibrosis can be halted or even reversed
depending upon the extent of its progression [157,158]. Currently, the regression of
fibrosis has been studied mostly in the liver [159,160]. It is associated with termination of
the chronic injury, loss of TGF-β1 signaling, and decrease of pro-inflammatory cytokines
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[161]. Recruitment of myelo-monocytic cells to the injured organ is critical for the
resolution of fibrosis [162]. Inflammatory cells not only participate in clearance of
collagen-producing cells, but also secrete matrix metalloproteinases (MMPs), which play
a crucial role in ECM remodeling and regression of fibrosis. However, advanced cirrhosis
in liver is resistant to collagenolysis due to formation of irreversible non-reducible
crosslinked collagen and an ECM enriched with elastin fibers preventing its degradation
[163]. This pathophysiologic state is considered the ‘‘point of no return’’ [163]. Severe
damage of the liver tissue resulting from the loss of the integrity of the basement
membrane due to the progressive deposition of collagen matrices in the space of Disse,
increased intrahepatic resistance to blood flow and portal hypertension finally lead to
hepatocellular carcinoma and that may also prevent resolution of fibrosis [164].
Since the contractile stresses of the surrounding microenvironment in fibrotic
disease progression are a key mediator in the differentiation of myofibroblasts, it is
suggested that alteration in the ECM biomechanical properties, stiffness in particular may
be an important therapeutic target that is able to modulate myofibroblast formation and
fibrosis [111,165]. Recent studies suggests that when valvular, liver, or lung fibroblasts
are cultured on low modulus substrates (E ≤ 10 kPA), they maintain a normal phenotype;
however, they are activated to myofibroblasts when they are cultured on higher modulus
substrates [111,165–168]. Marinkovic et al. tested whether matrix stiffness can control
the function of fibroblasts derived from idiopathic pulmonary fibrosis compared with
fibroblasts derived from normal lung tissue in collagen hydrogel substrates with the
stiffness spanning from normal and fibrotic lung tissues [111]. They demonstrated that
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the contractile and proliferative function in primary fibroblasts derived from fibrotic
lungs were significantly inhibited when they were cultured in soft matrices (~ 1 kPa of
elastic modulus), which is the physiological level of lung ECM stiffness, suggesting that
the myofibroblast phenotype is not a permanent state but can be reversed by alterations in
the matrix properties. Wang et al. utilized a photodegradable poly (ethylene glycol) (PDPEG) hydrogel to study the fate of valvular myofibroblasts in response to reduced
substrate modulus [165]. Their results indicated that valvular myofibroblasts grown on
soft substrates (7 kPa, mimicking healthy cardiac valve fibrosa) show a decrease in αsmooth muscle actin (α-SMA) stress fibers and proliferation and an increase in apoptosis,
while the levels of gene expression including α-SMA and CTGF were significantly upregulated when valvular myofibroblasts were cultured on stiff substrates (32 kPa,
mimicking pre-calcified diseased tissue). This study suggests that the mechanical
stiffness of the substrates can regulate the fate of activated myofibroblasts, resulting in a
predominantly quiescent fibroblast population. Thus, understanding the plasticity of the
fibrotic phenotype is critical to development of novel therapeutic approaches to fibrosis.
1.4. Current Antifibrotic Therapy and Limitation
The increasing evidence that fibrosis is a dynamic and reversible process, the
clarification of the underlying mediators of fibrosis progression, and advances in noninvasively assessing fibrosis have generated enthusiasm towards developing effective
antifibrotic drugs. To date, however, no drug has been approved as a clinically safe and
effective antifibrotic [169]. Challenges remain including the lack of the etiology and
pathogenesis due to the diversity and heterogeneity of fibrotic diseases and suitable
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surrogate parameters capable of measuring the effectiveness of novel therapeutic agents.
Here, recently ongoing studies regarding interference with TGF-β expression and
activation using small molecules or neutralizing antibodies are summarized.
1.4.1. Interfering with TGF-β Expression and Activation
As described earlier, TGF-β is the most important causative agent involved in the
fibroblast activation process as well as the mesenchymal transformation of epithelial and
endothelial cells [170]. Thus, preventing TGF-β signaling is clearly a potential
therapeutic approach that may be achieved at several levels. First, the complex signaling
pathways mediated by TGF-β receptor binding offer multiple points of potential
therapeutic intervention. TGF-β is also constitutively synthesized and stored in an
inactive form as a complex with specific binding proteins. Thus, the expression of TGF-β
and the process of its release in an active form represent promising therapeutic targets.
Pirfenidone (5-Methyl-1-phenyl-2-(1H)-pyridone), marketed under the names
Esbriet and Pirespa is a small orally bio-available molecule that is the first targeted
antifibrotic drug to be approved for the treatment of IPF in Europe and Japan [84,169].
Pirfenidone exhibits antifibrotic and anti-inflammatory properties in a variety of in vitro
and animal models [171–173]. In vitro studies have demonstrated that pirfenidone
inhibits TGF-β-induced collagen synthesis [171,172], decreases ECM deposition and
blocks the mitogenic effects of PDGF in lung fibroblasts derived from patients with IPF
[173]. Pirfenidone has also shown broad antifibrotic activity in several animal models of
fibrosis in lung and other organs. In pulmonary fibrosis study, pirfenidone reduced
fibrosis in response to bleomycin, lung transplant and repeated allergen exposure through
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the suppression of TGF-β gene expression and significantly reduced the synthesis of
collagen type I and III. Pirfenidone has been extensively evaluated through open-labeled
compassionate use studies followed by four randomized, double-blind, placebocontrolled clinical trials, phase III studies. The almost identical multinational 004 and 006
trial studies were conducted, and the third trial was performed in Japan [174,175]. In the
004 trial, 435 patients with IPF were assigned in a 2:1:2 dosing ratio to 2,403 mg/day
pirfenidone, 1,197 mg/day prifenidone, and placebo. In the 006 study, 344 patients were
assigned to either 2,403 mg/day of pirfenidone or to placebo. In study 004, pirfenidonetreated patients exhibited increased forced vital capacity (FVC) (P = 0.001) compared
with the placebo group (difference 4.4%, 95% CI, 07 to 9.1), however in study 006, the
change in FVC at 72 weeks was not significant between the treatment and placebo groups
(P = 0.501). In the double-blind, placebo-controlled randomized clinical trial conducted
by Taniguchi et al., pirfenidone was administered in a 2:1:2 ratio (1,800 mg/day, 1,200
mg/day or placebo) to a total of 275 patients over a 52 week period [174]. The primary
endpoint, a change in lung vital capacity, was significantly preserved in the higher dose
versus placebo group (– 0.09 vs. – 0.16 L respectively, P = 0.0416). Limitations to this
study include the enrollment of a relatively homogeneous Japanese population, as well as
the fact that the primary end-point was changed before unblinding. In an exploratory
analysis of this study later published by Azuma et al., it was observed that a
subpopulation of these patients had a greater benefit from pirfenidone [176]. A wellknown side effect of pirfenidone, photosensitivity, was also frequently observed in this
study (51% of patients in the high-dose group and 53% in the low-dose group). Despite
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an approval by both the EU and Japan, due to the lack of therapeutic efficacy of
pirfenidone in FVC and survival benefit, the use of pirfenidone for treating pulmonary
fibrotic diseases has not been approved by the FDA. A new phase III trial of pirfenidone
aiming to detect a clinically meaningful effect on FVC is therefore underway in the
United States (the ASCEND trial).
Many neutralizing antibodies to TGF-βs have been successfully shown to prevent
fibrosis in a number of organs in animal models through their direct binding to TGF-β
ligands [177]. Due to TGF-β’s pleiotropic, multiple roles in immunomodulation, tumor
suppression, and wound healing, the broad targeting of TGF-β ligand to treat chronic
disease in humans may have detrimental side effects [34,178,179]. For example,
inhibition of TGF-β receptor type I prevented the overexpression of collagen type I and
enhanced ECM contraction by fibrotic dermal fibroblasts isolated from scars of
scleroderma patients. However, it also significantly affected basal collagen type I
production and ECM contraction by normal fibroblasts. In addition, one patient
developed a premalignant skin lesion while receiving a TβRII antibody, but upon
discontinuation of the drug, this effect resolved with time. Moreover, TGF-β is known to
stimulate angiogenesis by upregulation of VEGF, which can be blocked by a treatment
with TGF-β neutralizing antibodies. Furthermore, the pre-clinical success of TGF-βtargeting antibodies has not translated into clinical efficacy. First, the human monoclonal
antibody metelimumab (also known as CAT-192) was clinically investigated and
compared with placebo in 45 patients with early systemic sclerosis. In this clinical trial,
the antibody was given by intravenous infusion at baseline and at weeks 6, 12 and 18, and
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patients were evaluated at 24 weeks. The trial showed no improvements in skin scores
and other disease manifestations in patients treated with CAT-192. Limitations of the
study include the restricted isotype specificity of the antibody and its low binding
affinity, the short treatment duration and small number of patients. A monoclonal
neutralizing antibody to TGF-β2 (lerdelimumab, or CAT-152) has also been tested for the
prevention of scarring following glaucoma surgery. In addition, a monoclonal antibody
(GC1008) targeting all three TGF-β isoforms is currently in a phase I trial for treating
idiopathic pulmonary fibrosis. However, results to date in humans have not been
promising.
1.4.2. Blocking TGF-β Signaling Pathways including TGF-β receptors and SMAD
molecules
There have been several studies of specific inhibitors of TGF-β type l receptor
and the most thoroughly studied is SM305 that proved to have excellent selectivity and
potency against ALK5 and ALK4. In normal dermal fibroblasts, SM305 abrogated TGFβ-induced ECM gene expression, fibrogenic cytokine production, Smad3- and Smad2dependent

transcriptional

responses,

and

fibroblast

transdifferentiation

into

myofibroblasts. These inhibitory effects of SM305 were associated with potent selective
suppression of TGF-β-induced phosphorylation and nuclear translocation of R-Smads.
However, in unaffected SSc fibroblasts, SM305 only caused variable and modest
reduction in levels of type I collagen, and did not reverse constitutive Smad nuclear
accumulation or the proportion of α-SMA-positive myofibroblasts. The contradictory
results with SM305 in SSc fibroblasts therefore indicate that the suitability of the kinase
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inhibitor to target TGF-β must be carefully considered due to complexity and
heterogeneity of fibrotic reactions and thoroughly evaluated in animal models and
ultimately, possibly in humans.
Preventing TGF-β action is clearly a promising therapeutic approach for many
fibrotic diseases, however, evidence from the clinical applications revealed undesired
side effects due to the multi-functional activities of TGF-β and consequent systemic side
effects [126,179–181]. Therefore, the development of novel antifibrotic therapies is
desperately needed.
1.5. Mechanotherapy
Cells and tissues are capable of responding and adapting to their mechanical
environment. Mechanical forces direct cellular activities influencing the tissue-level
processes of growth, remodeling, and repair, with the ultimate outcomes being altered
tissue mass, structure, and function. In 1890, mechanotherapy was first defined as “the
employment of mechanical means for the cure of disease” [182]. Typical examples of
classical physical therapies are massage and orthopedic rehabilitation that aim to promote
symptom relief or functional recovery towards pre-surgical levels with or without the
help of specific operational equipment or devices [183]. More recently, the definition of
mechanotherapy has expanded to include “any intervention that introduces mechanical
forces with the goal of altering molecular pathways and inducing a cellular response that
enhances tissue repair and remodeling” [184]. Thus, mechanotherapy describes a group
of therapeutic interventions intended to reduce and reverse injury to damaged tissues or
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promote the homeostasis of healthy tissues by mechanical means at the molecular,
cellular, or tissue level [183–185].
1.5.1. Mechanotransduction
Mechanobiology is an interdisciplinary field that investigates cells’ biological
responses to mechanical stresses and the mechanotransduction pathways by which these
loads are transduced into a series of cellular and molecular events [186].
Mechanotransduction

is

generally

broken

down

into

four

phases:

(1)

the

mechanocoupling phase, where the external mechanical signal is converted into a
mechanical signal in the vicinity of the cell; (2) biochemical coupling, where the local
mechanical signal is transduced into a biochemical signal, resulting ultimately in genetic
or protein changes; (3) signal transmission, where the biochemical signal is then passed
from the sensor cells to the effector cells; and (4) the effector cell response [183,184].
When the cells are exposed to a variety of micromechanical stimuli such as
tension, compression, shear, hydrostatic pressure, vibration, and fluid shear,
transmembrane integrins transfer mechanical forces from the extracellular matrix (ECM)
to the cytoskeleton through focal adhesion complexes. This activates signal transduction
cascades, which in turn alter cytoskeletal functions and induce ECM remodeling. The
actin cytoskeleton can thus act as a ‘global mechanical signal integrator’ [183].
The conversion of mechanical stimuli to the mechanochemical signal can be
explained through the tensegrity networks proposed by Ingber et al [187]. The tensegrity
architecture of the cytoskeleton is a self-assembling system driven by structural
hierarchies and the tensile stresses of the cell that yields a dynamic balance between
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counter-acting forces of compression and tension, then finally leading to a selfequilibrated mechanical stability [188,189]. Within a tensegrity network, mechanical
forces received by the cytoskeleton of a cell from the ECM not only change the cell that
receives the signals but are also transferred to neighboring cells through cadherinmediated cell–cell adhesion complexes. Thus, cells connected to each other and to the
ECM form a dynamic network that can be manipulated by externally applied mechanical
stimuli. Based upon the recognition that a wide range of intracellular signaling molecules
and enzymes bind to the actin cytoskeleton, Ingber and co-workers have proposed a
theory of ‘solid-state biochemistry’ for mechanical-chemical conversion within cellular
tensegrity structures in which cytoskeletal re-arrangements in response to mechanical
forces create changes in enzyme conformation/activity and enzyme/substrate proximity
[190].
Several researchers also highlight the transcriptional regulation by cytoskeletal
forces inside the nucleus [191–193]. Cytoskeletal filaments are connected to the nuclear
membrane through the linker of nucleoskeleton and cytoskeleton complex (LINC
complex). Within the complex, a family of nesprin and SUN-domain proteins play an
important role in connecting the actin cytoskeleton with the lamina nucleoskeleton
[191,194,195]. Nesprins 1 and 2 bind actin filaments, nesprin 3 binds plectin associated
with intermediate filaments, and nesprin 4 interacts with microtubule networks through
the molecular motor kinesin 1. The C-terminus of nesprin proteins contains a KASH
domain that binds SUN1 and SUN2, and SUN domain is located in the nuclear envelope
[196]. The N-terminus domain of SUN proteins binds to lamins and other structural
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proteins of the nucleoskeleton [194]. The lamin proteins can bind to DNA and chromatin
through complexes of lamin binding proteins and other structural proteins, including
transcriptional repressors and regulators. Thus, externally applied mechanical stimuli
transmit from the ECM through the cytoskeleton via integrin-mediated interactions and
then finally into DNA and chromatin bound to the nucleoskeleton through the LINC
complex.
Of particular interest currently in integrin-mediated mechanisms is the transient
receptor potential (TRP) superfamily that are mechanosensitive ion channels that are
activated by multiple endogenous and external stimuli to mediate a wide variety of
mechanotransduction processes in diverse organs and species [197–200]. The TRP
superfamily is composed of 28 different genes that are divided into seven different
subfamilies (TRPA, TRPC, TRPM, TRPML, TRPN, TRPP, and TRPV). They are known
to be activated by the following: 1) direct ligand binding, 2) depletion of intracellular
Ca2+ store and Ca2+/calmodulin-dependent activation, and 3) indirect activation by
osmotic stress, temperature variation, pheromones, taste, and mechanical as well as other
stimuli [199,201]. In particular, there are two models (direct or indirect) for activation of
TRP ion channels by mechanical stimuli [202,203]: a) direct activation by force
conveyed through externally stretched lipid, b) direct activation by force conveyed
through linker proteins that are bound to both TRP channel proteins and adhesive
proteins such as intracellular cytoskeletal elements and/or extracellular matrix molecules,
c) indirect activation by force conveyed to accessory proteins that are anchored to
channel proteins. The accessory proteins are bound to a mechanically sensitive proteins
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that carry the signal into a ligand-activated channel, and d) indirect activation by a
secondary signal such as a diffusible second-messenger molecule or activation of a kinase
generated by a force-sensing protein complex. Resulting from these changes, the TRP ion
channels open or close, allowing the influx or efflux of potassium and calcium ions,
leading to alteration in molecular and cellular functions.
Furthermore, cells receive these exogenous forces through interaction with the
ECM, and the stiffness of the ECM substrates is an important mechanical determiant of
cell behavior [204]. Several studies also suggest that the alteration in substrate stiffness
affects cellular function and changes the structure and composition of the ECM,
eventually leading to the changes in tissue development, homeostasis, and wound healing
[205–214]. Flanagan et al. developed the protein-laminated polyacrylamide gels with
varying amounts of bisacrylamide to generate substrates with variable elastic moduli.
Mouse primary neuronal cells cultured on softer substrates (E ~ 0.1–1 kPa) showed
threefold increased formation of neurite branches compared with those grown on stiffer
gels [215]. Engler et al. used micropatterned collagen-coated poly-acrylamide (PA) gel
substrates to investigate the effect of matrix stiffness in striated muscle differentiation
[216]. 4 weeks after plating myoblasts on collagen-coated PA gels of varied stiffness,
myoblasts cultured on the matrices that mimic striated muscle like-elasticity (E ~ 8–17
kPa, intermediate stiffness) showed significant myosin striation and myofibril maturation
compared with the cells grown on soft or rigid substrates. Cells on rigid substrates
produced well-formed stress fibers and numerous vinculin-enriched focal adhesions, but
did not achieve actin reorganization into myosin striations. On the other hand, cells on
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soft substrate did not form strong adhesion and contractile forces, resulting in poorlyorganized inter-cytoskeletal structures and lack of striations. In addition, osteoblast
differentiation from human mesenchymal stem cells has been shown to occur on stiffer
substrates (E ~ 25–40 kPa) that mimic the cross-linked collagen of osteoid [217–219].
These results show that mechanical properties of the substrate specifically direct specific
lineage differentiation of mesenchymal stem cells, which are critical for tissue
development and regeneration. Thus, understanding of how biomechanical forces can be
transmitted and influence cell behaviors will also help elucidate the pathogenesis of many
diseases [177,220,221], and hence provide new mechano-therapeutic approaches to treat
these pathological conditions more effectively.
1.5.2. Effect of Mechanical Stimulation on ECM Remodeling-related Molecules
Mechanical forces are essential regulators of tissue homeostasis and development
and indispensable for normal function, particularly of connective tissues comprised
mainly of fibroblasts, as they are subjected to various forms of mechanical loadings such
as tension, compression, and sheer stress in the organism. It has been demonstrated that
mechanical forces specifically regulate the synthesis and degradation of various ECM
components such as collagen, GAGs and proteoglycans. Since the first study illustrating
the effect of mechanical loading on ECM production was reported by Leung et al. [222],
numerous studies have shown that mechanical loading is able to affect fibrous
procollagen expression depending on the cell source and loading conditions [221,223].
For example, compared to the unstretched cells, a single application of a 10% uniaxial
stretch resulted in a threefold increase in collagen type I, III and fibronectin mRNA levels
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in cardiac fibroblasts [224]. However, when cardiac fibroblasts were stretched for 20%, a
significant inhibition of ECM-related genes was observed [225].
In response to cyclic strain, anterior cruciate ligament (ACL) and medial
collateral ligament (MCL) fibroblasts have shown a differential mRNA expression in
collagens type I and III after stretching [226]. ACL fibroblasts exhibited higher levels of
type I collagen mRNA with no apparent changes in type III collagen mRNA, whereas
MCL fibroblasts responded to cyclic strain by a significant increase in type III collagen,
but not in type I collagen mRNA. Interestingly, in contrast to many other studies, Jiang et
al. reported that human skin fibroblasts grown on mechanical stretch device with 20%
cyclic stretching and 1 Hz frequency for 6 days showed a significant reduction in
collagen type 1 expression, but also observed a significant increase of collagen type 1 in
response to non-stretch and static stretch conditions [227].
Connective tissue cells have also been found to be responsive to the
characteristics of applied loading, including strain magnitude and frequency. In human
tendon fibroblasts, when cells were subjected to uniaxial stretching with constant
frequency and duration (0.5 Hz, 4 hr), but various magnitudes of stretching (~ 4–8%),
cell proliferation, collagen type I gene expression, and protein production all increased in
a stretch magnitude-dependent manner [228]. Periodontal ligament fibroblasts (PDLFs)
exhibit differential responses to varying levels of mechanical strain as well. A 5% cyclic
stretch for 24 hours increased synthesis of both collagen type I (twofold) and fibronectin
(threefold) [229]. However, exposure to a 10% strain exhibited a similar response for
fibronectin (fivefold increase), whereas the amount of type I collagen synthesized by the
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stretched cells did not differ from unstretched control levels, showing that these cells are
capable of modifying their responses to varying magnitudes of tensional stress. In
addition, adult cardiac fibroblasts also show differential responses to different stretching
magnitudes. A cyclic tensile strain at 3% increased mRNA expression levels of collagen
type III and fibronectin by 1.5-fold; however, 6% stretching decreased collagen type III
mRNA levels while fibronectin levels remained unchanged [225,230]. Furthermore, the
effect of cyclic stretching variables such as strain, pulse shape, and pulse frequency has
been reported for human dermal fibroblasts [231]. Joshi and Webb examined dosedependent responses of cell/scaffold stiffness to systematic variation in cyclic parameters
including strain amplitude, rate, frequency, and duration, and demonstrated that varying
cyclic strain regimes differentially regulated construct mechanical properties [231].
Concomitant with increased expression of collagen type I in response to
mechanical loads, numerous studies have shown that mechanical stress also stimulates
increased expression of TGF-β1 in a number of cell and tissue types [228,232–237],
which in turn serves as an underlying mechanism for strain-mediated effects on ECM
expression, particularly collagen synthesis and accumulation. Several studies indicated
that collagen α1 type 1 gene expression induced by mechanical stress is mediated by the
autocrine or paracrine release of transforming growth factor (TGF)-β [232,238–241]. In
addition, mechanical loadings can lead to the activation of pre-existing TGF-β in the
ECM of myofibroblasts that can stimulate the target genes such as procollagen α1 type 1
[242]. When the fibroblasts were subjected to mechanical stress, not only the secretion of
active TGF-β is stimulated, but also the mRNA expression of TGF-β is enhanced via
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activation of EGR-1 (Early growth response protein 1) which has three zinc finger motifs
to bind and regulate transcription in many growth factors and cytokines [243].
Specifically, with regard to fibroblasts, tendon fibroblasts cultured under cyclic uniaxial
stretching (4% and 8% constant stretching at 0.5 Hz for 4 h) showed increased expression
of TGF-β compared to that of non-stretched fibroblasts [228]. Also, the increased
expression of TGF-β1 in response to cyclic strain at 1 Hz (per cycle 0.5 sec elongation
and 0.5 sec relaxation) for 4 h has been reported for cardiac fibroblasts [244]. Cyclic
stretching increased levels of TGF-β1 by 21 ± 4% upon 4 h of cyclic stretching.
Furthermore, the mRNA synthesis and protein production of CTGF are also induced by
mechanical stress [245]. CTGF expression was upregulated by more than twofold in 4 h
and remained elevated at this level after 8 h, when mesangial cells are subjected to cyclic
mechanical strain [246]. Schild and Trueb also noted a substantial increase (fourfold) in
the levels of CTGF mRNA in mechanically stressed fibroblasts [245].
Additionally, recent studies have shown that mechanical loading of cells also
modulates ECM turnover by regulating the expression of MMPs and their activity.
Human dermal fibroblasts cultured under cyclic stretching (20%) at low frequencies (0.1
Hz) for 24 h produced a significant increase in MMP1 and type I collagen mRNA levels
compared to nonstretched controls. TIMP1 synthesis was significantly induced by
mechanical tension compared with unloaded control at 72 h to 96 h of culture. The results
demonstrated that the level of TIMP1 increased 63.9% at 24 h; and 64.42%, 57.1%, and
69.9% at 48 h, 72 h and 96 h of culture, respectively [247]. In addition, cDNA microarray
study performed by Kessler et al. demonstrated that human dermal fibroblasts cultured
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within three-dimensional collagen networks under stressed condition exhibited significant
increase in the MMP1 and tissue inhibitors of matrix metalloproteinases (such as TIMP1
and TIMP3) compared with relaxed conditions [38].
1.5.3. Current Mechanotherapy in Wound Healing
Mechanotherapies focusing on improving wound healing include negative
pressure wound therapy (NPWT), shockwave therapy and surgical tension reduction.
First, NPWT is known clinically as vacuum-assisted closure (VAC) and involves the
application of a vacuum to a wound surface by sealing the wound with a porous
polyurethane sponge and occlusive dressing connected to the vacuum [248]. It is
effective for treating acute wounds as well as chronic, open, large, and contaminated
wounds [249], because it can remove extracellular fluid, stabilize the wound
environment, generate contracture of the wound or macrodeformation, and induce
microdeformation at the foam–wound interface in the wound area [250]. In addition, it
has been shown to promote angiogenesis through increased VEGF production [251,252].
Furthermore, there is in vitro evidence showing that NPWT of human dermal fibroblasts
in a provisional wound matrix elevates the concentrations of TGF-β, platelet-derived
growth factor-α (PDGF-α), and PDGF-β [253]. Similarly, mouse dermal fibroblasts
treated by a suction/foam/perfusion bioreactor in vitro exhibit upregulation of basic
fibroblast growth factor (bFGF), TGF-β1, Type I collagen α1, and smooth muscle actin
α2 mRNA expression [254].
Extracoporeal shock wave therapy (ESWT) is currently being investigated to
enhance wound healing. This approach involves biphasic high-energy acoustic waves that
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can be generated by electrohydraulic, electromagnetic, or piezoelectric technologies.
Clinical outcomes suggest that ESWT is effective in both diabetic [255] and surgical
wounds

[256]

by

reduced

wound

size

[257],

enhanced

re-epithelialization,

neovascularization, and blood perfusion [258–260], and decreased pain and necrosis
[261,262]. At the molecular level, shockwave therapy upregulates TGF-β1 expression in
fibroblasts [263] and suppresses the production of the pro-inflammatory cytokines IL-1β,
IL-6, and TNF-α [264]. It also triggers anti-inflammatory activity by, for example,
increasing neuronal NO synthase (nNOS) activity and NO production in the C6 rat
glioma cells while concomitantly downregulating NF-κB and TNF-α gene expression
[265]. Shockwave therapy has been recently investigated as an adjuvant therapy in the
treatment of acute and chronic wounds [266].
In addition, mechanotherapies are highly useful for preventing and treating
pathological scars and reducing their recurrence. The association of pathological scars
with skin tension has been well-documented: most of these scars occur in areas of the
body that are subjected to frequent mobility and/or high stretching tension [267].
Significantly, mechanical stress applied to an injured area produces hypertrophic scars in
mice [268]. These destructive local mechanical forces on the wound can be alleviated by
employing refined surgical tension-reducing techniques, such as a small-wave incision
design [269], local flaps to cover the wound, silicon sheeting [270], and
subcutaneous/fascial sutures [271]. Recently, a stress-shielding technique based on a
dynamic polymeric device reduced the histological scar area of incisions in swine by 9fold compared with incisions in a stressed state; a subsequent Phase I clinical study
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showed that the stress-shielding device decreased hypertrophic scar formation in humans
with high-tension abdominoplasty incisional wounds that are prone to excess scarring
[272].
It is widely noted that mechanical forces can activate intercellular biochemical
signals through the mechano-responsive transmembrane and ECM molecules and then
lead to molecular and cellular responses via altered activation of downstream signaling
pathways. Despite successful clinical outcomes in orthopedic and wound healing
practices, more in-depth discussion on the intracellular molecules and molecular
signaling pathways responsive to mechanical stress are needed. In addition, huge
challenging questions remain in the developments of mechanotherapy, particularly
specificity, selectivity, and timeliness with regard to the application of mechanical forces.
More specifically, dosing parameters such as type, amplitude, duration, and frequency
need to be carefully investigated to make a novel therapy more specific and effective
[183].
1.6. Vocal Folds
1.6.1. Vocal Fold ECM and Biomechanics
Voiced sound is produced by vibration of the vocal folds, which converts
aerodynamic energy from exhalation to acoustic energy. The unique biomechanical
properties of the vocal folds result from its distinctive, hierarchal ECM composition and
organization that allow them to undergo high frequency oscillations. The vocal folds are
stretched across the larynx located between the trachea and the pharynx. Each fold has a
length of 10–20 mm along the anterior-posterior direction and a thickness of 3–10 mm.
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The human vocal folds can be divided broadly, anatomically into three tissue layers:
stratified squamous epithelium, lamina propria, and vocalis muscle anchored to the
thyroid and arytenoid cartilages.
Hirano et al. first subdivided the vocal fold lamina propria into superficial,
intermediate, and deep layers based upon histological composition [273–277]. The
epithelium and the superficial layer of lamina propria comprise vocal mucosa. The
gelatinous superficial layer (Reinke's space) of the lamina propria has a small number of
cells and is composed of loosely clustered reticular collagen fibers and small, amorphous
forms of elastin fibers arranged in a longitudinal directions. This layer functions as a
pliant cushion during vocal fold phonatory cycles, providing resistance to impact stresses
during phonation [278,279]. Anchoring looped collagen fibers in the superficial lamina
propria form an intertwined network, which is highly branched, delicate threedimensional matrix filled with large amount of glycoproteins, GAGs, and elastic fibers.
The vocal ligament contains the intermediate and deep layers of the lamina propria. The
intermediate layer is composed of mostly mature elastin fibers arranged in parallel to the
edge line of the vocal fold. This layer provides elastic mechanical integrity to the vocal
fold. Finally, the deep layer of the lamina propria is composed entirely of mature collagen
fibers and coiled elastin. With regard to the ECM distribution, collagen types I and III
generally exist in all of the layers in the vocal folds, whereas collagen type III is
dominant in the lamina propria, particularly in the intermediate and deep layers of vocal
folds [280]. Munoz-Pinto et al. demonstrated that the average thickness and angular
deviations of collagen fibers increase with depth toward the thyroarytenoid muscle [281].
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Elastin that contributes to tissue pliability and elasticity is located in the intermediate
layer of vocal fold lamina propria at highest density [282]. Hyaluronic acid (HA) is
highly concentrated in the intermediate layer of vocal folds and provides the gel-like and
cushioning characteristic to the structure [283]. Decorin and fibromodulin, small
proteoglycans found primarily in the superficial layer of the lamina propriaare known to
bind collagens and regulate the collagen fibril formation in vocal fold tissue [284]. The
unique arrangement of vocal fold ECM, therefore, allows the vocal folds to resist
longitudinal forces during phonation, while permitting mucosal vibration in the lateral
plane.
Voice production is initiated and regulated by the coordination of many different
factors, including respiration (air pressure and flow), phonation (vocal fold
biomechanical property), and resonance (the cavities above and below the glottis) [285].
During exhalation, the air coming out from the lungs encounters the vocal folds postured
at the midline. As the pressure and flow of the air rise above the phonation threshold
pressure (PTP), air begins to pass through the glottis. At this point, the elastic properties
of the vocal ligaments and the Bernoulli’s forces generated by the air pressure difference
between the cavities above and below the vocal fold tissues bring vocal folds to the
midline. The vocal folds, thus, open and close repeatedly, resulted in the production of
vibratory patterns at frequencies of around 200−220 Hz for women and 100−120 Hz for
men. This rapid vibration of the vocal folds generated by repetitive vibratory cycles
produces “voiced sound” after amplification and modification by the vocal tract
resonators [286].
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The cover-body theory of vocal fold vibration originated by Hirano and Kakita
proposed that the relatively compliant vocal mucosa (cover) oscillates over the relatively
stiff vocalis muscle (body) along with the vocal ligament serving as a transition zone
[287]. The vibration of the vocal fold mucosa is characterized as a mucosal wave that
propagates in the horizontal, longitudinal, and vertical planes at physiological frequencies
ranging from 100 to 300 Hz and amplitudes of 1–2 mm during normal phonation [288].
On the other hand, the vocal ligament oscillates at lower frequencies of 1–10 Hz and
experiences maximum tensile strains estimated to range from 15–60% [289,290].
Vocal quality depends on the vocal fold extracellular matrix (ECM) composition
and organization. With regard to age, the distinctive multi-layer structure of vocal folds
was not clearly observed in newborn vocal folds [291,292]. As the vocal folds undergo
substantial growth and maturation during adolescence, the unique matrix composition
and multi-layered formation of lamina propria were identified between ages 13 through
17 [292,293]. In addition, biomechanical and compositional changes in vocal folds have
been reported with respect to gender. The levels of hyaluronic acid in lamina propria are
about three times greater in men than those in women, which is observed by increased
lamina propria thickness for men [294]. Furthermore, increased elasticity and viscosity
are observed in men and geriatric patients relative to women and younger patients [295–
297].
Regarding vocal fold injury, excessive mechanical stresses imposed by prolonged
phonation, a complication of surgical procedures, or chemical damages can lead to vocal
fold scarring. Histological examination has reported compositional alterations after vocal
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fold injury, including increased type I and III collagens, increased fibronectin deposition
and decreased elastin density and organization [298]. The consequence includes
incomplete generation of vibration caused by imperfect vocal fold closure during
phonatory cycles. Thus, based on previously published studies and observations, the
complete biomechanical function of the vocal folds is supported and maintained by the
dynamic interactions of its unique matrix components.
1.6.2. Scarless Wound Healing of Vocal Folds
Vocal fold damage resulting from a multitude of factors, such as traumatic injury,
intubation, phonotrauma, gastroesophageal reflux disease, chemical irritation, and the
surgical treatment of benign, chronic infections ultimately leads to complete loss of vocal
function. Although the regenerative capability of the vocal folds is clearly limited
depending on the magnitude of tissue injury, several researchers highlight the antiscarring property of vocal fold lamina propria. Based on the histological observation
reported by several researchers, the presence of myofibroblasts and macrophages in
healthy vocal tissue in the superficial lamina propria layer suggested that the mechanical
stresses imposed during normal phonation result in repetitive microtrauma that is repaired
without significant compositional, structural, and functional losses [284,293,299,300].
Although the mechanisms underlying scarless repair of vocal fold injury in the LPs have
not been fully elucidated, several studies suggest that the ECM components of the vocal
fold SLLP provides resistance to scar formation. For example, hyaluronic acid (HA) is
known to play an important role not only in proper vocal fold vibration by contributing to
the viscoelastic properties of the vocal fold cover as a space filling material, but also in
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the acute phase of wound healing. For example, HA has been shown to inhibit fibroblast
collagen synthesis and deposition [301,302]. Human dermal fibroblasts cultured in the
media with the addition of HA (0.5 and 1 µM) showed decreased production of ECM,
particularly collagen synthesis, compared with the collagen levels produced by
fibroblasts cultured in the absence of HA supplementation. They also indicated that high
concentrations of HA in the ECM during wound healing reduced the deposition of ECM
proteins, thus resulting in the wound healing process with less scar formation [302].
Furthermore, several studies indicated that two small proteoglycans: decorin and
fibromodulin, predominantly located in the superficial layer of the lamina propria (SLLP)
are associated with anti-scarring activity. Both molecules are known to bind collagen,
alter the kinetics of fibril formation [303], and inhibit fibrillogenesis [303–305].
Decreased levels of both decorin and fibromodulin have been observed in the fibrotic
scar formation in the skin [280,306]. Reduced levels of decorin and fibromodulin may
contribute to the altered collagen structure associated with vocal fold scarring. Moreover,
both proteoglycans have been shown to bind and sequester TGF-β1, a potent fibrotic
cytokine that stimulates collagen synthesis during scarring and fibrotic disease
[278,304,307–311]. Decreased TGF-β-mediated matrix accumulation and glomerular
injury were also reported after the addition of decorin to a rat model of
glomerulonephritis [312].
Many studies demonstrated that the anti-scarring property of vocal fold lamina
propria resulted from its unique matrix composition. Several lines of evidence also
showed that matrix composition can be modulated and regulated by mechanical forces
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through mechanotransduction pathway. Therefore, since the vocal folds extensively
experience unique mechanical stresses, we have questioned whether vibratory stimulation
can provide the resistance to vocal fold scarring via activation of altered downstream
signaling molecules and pathways.
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CHAPTER TWO
PROJECT RATIONALE
2.1. Specific Aims
Fibrosis is a complex disease predominantly characterized by excessive and
abnormal fibrous ECM deposition, leading to the failure of various organs: lung, liver,
kidney and skin. During the normal wound healing process, activated myofibroblasts
migrate into the wound area, where they rapidly synthesize and remodel newly created
ECM to maintain tissue integrity during repair. Fibrotic disorders result from
dysregulation of this process, commonly involving the abnormal persistence of several
pro-fibrotic cytokines that leads to sustained myofibroblast activation and ongoing ECM
synthesis. Specifically, TGF-β is considered a master switch that activates critical
downstream molecules in the progression of fibrotic disease [24,123–126,133,159].
Although various strategies designed to interfere with TGF-β expression, receptor
binding, and signal transduction have been studied, a clinically safe and effective therapy
has not yet been developed.
Recently, many researchers highlight mechanical forces as therapeutic tools,
especially focusing on how mechanical forces can be applied to promote wound healing
or reverse pathological processes. Mechanical stimulation plays a central role in
regulating ECM composition and organization and cytokine production during
development and wound healing. Vocal fold tissues differ from other connective tissues
in terms of their unique biomechanical and biochemical properties. The vocal mucosa
(epithelium and superficial layer of lamina propria (SLLP) is continuously exposed to
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high frequency vibration, while the vocal ligament (intermediate and deep layers of
lamina propria) experiences lower frequency cyclic tension. Collagen density increases
with depth in the lamina propria, suggesting that differences in the mechanical
microenvironment are able to stimulate differential expression of ECM-related genes.
The presence of macrophages/myofibroblasts in the SLLP of healthy patients suggests
that vibratory stress combined with impact stress when the two folds collide at the
laryngeal midline results in repetitive microtrauma. However, the limited amount of
mature collagen further suggests that the SLLP possesses the capability to continuously
repair this damage without permanent scarring. Therefore, the objective of this research is
to understand the mechanisms regulating fibroblast matrix metabolism in the SLLP and
investigate the potential of vibratory stimulation for treatment of fibrotic diseases. The
specific aims are:
Aim 1: To characterize transcriptional and translational response of human dermal
fibroblasts activated by vibratory stimulation. Vibratory stimulation has been reported to
increase the expression of matrix-related genes consistent with the native vocal fold
tissue physiology and potentially provide resistance to scarring, including downregulation of type I collagen. This study is the first to characterize the comprehensive
transcriptional response of human dermal fibroblasts to high frequency vibration and to
identify down-regulation of the TGF-β signaling pathway triggered by vibratory
stimulation. Normal human dermal fibroblasts (NHDF) seeded in porous polyurethane
substrates were subjected to either: 1) further static culture (Static), 2) one-time 20%
axial strain followed by static culture (1X Strain), or 3) one-time 20% axial strain
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followed by vibration (1X Strain + Vibration, 100 Hz frequency, 3.8 Vrms, 1.28 ± 0.07
mm amplitude). Microarray analysis was conducted to examine the transcriptional
response caused by vibratory mechanical stimulation. qRT-PCR and ELISA assays were
then performed to validate the microarray results for cytokine and collagen expression at
the 6 h time point and investigate if these changes were maintained up to 7 days. The
effects of vibratory stimulation on collagen deposition and mechanical stiffening of
polyurethane substrates were evaluated using two in vitro fibrotic models.
Aim 2: To characterize the effect of different vibratory regimes on fibroblast
matrix synthesis. Vibratory stimulation is characterized by three principle characteristics
(frequency, amplitude, and duration). Biomechanically, vocal fold mucosa experiences
vibration at high frequency (100–200 Hz) and oscillates approximately 1 mm laterally
during each vibration cycle. Many mechanical stimuli are known to elicit dose-dependent
responses, including varying levels of increased or decreased expression of genes and
proteins, collagen production, and mechanical stiffness. The goal of this study was to
investigate the effect of variable vibratory frequency, amplitude, and duration on the
expression of human dermal fibroblast ECM-related genes by quantitative real-time RTPCR. Thus, this study will allow complete understanding of the relationship between
variable parameters and responses, providing a first step towards identification of optimal
treatments for vibratory therapy.
Aim 3. To evaluate the potential therapeutic efficacy of vibration for reversing the
fibrotic phenotype in scleroderma-derived fibroblasts. The fibroblasts from patients with
systemic sclerosis (SSc) are known to exhibit an abnormal phenotype with expression of
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excessive amounts of ECM components, cytokines, and growth factors, including
collagens, and tissue inhibitors of metalloproteinases. Specifically, the profibrotic
cytokine TGF-β and its signaling pathway have been proposed to play important roles in
the activation of SSc fibroblasts. This study will test the hypothesis that vibratory
stimulation can reverse fibrotic pathological changes in matrix metabolism, restoring
gene expression, collagen synthesis, and mechanical stiffness to levels not significantly
different from normal skin fibroblasts.
2.2. Significance and Innovation
The United States government estimates that 45% of deaths in the United States
can be attributed to fibrotic disorders [16,89]. Almost every major organ system is
susceptible to fibrotic diseases; examples include pulmonary fibrosis, renal fibrosis, liver
cirrhosis, arteriosclerosis, and scleroderma. Although considerable progress in the
regression of fibrosis using TGF-β blocking strategies has been achieved over the past
few years, the clinical application of these approaches is still limited because of the
pleiotrophic activities of TGF-β and consequent side effects of systemic inhibition
[126,180]. Therefore, the development of novel mechano-therapeutic approaches, with
the opportunity for site-specific application and flexibility in handling and controlling
doses, will address the limitations of current paradigms for antifibrotic therapies.
Recently, the role of mechanical loading has drawn significant attention for its role in
pathology and as a potential treatment [183]. Mechano-therapeutic approaches have
potential benefits in specifically delivering mechanical stimuli to a target lesion, while
conventional drug therapy systemically affects every tissue and organ. Currently,
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mechanotherapies including microdeformational wound therapy (MDWT), shockwave
therapy, soft tissue expansion, distraction osteogenesis, and surgical tension reduction are
mainly focusing on treating and improving wound healing at the tissue level [183],
however, the molecular mechanisms underlying the efficacy of these approaches remain
to be thoroughly elucidated.
Chapter 3 will demonstrate that vibratory stimulation leads to the down-regulation
of TGF-β signaling and inhibits collagen production and mechanical stiffening that are
key phenotypic alterations observed in the tissues with fibrotic diseases.
In addition, development of mechano-therapeutic approaches has proven very
challenging, particularly with regard to specificity, selectivity and timeliness [126,180].
Specific type, amplitude, duration, and frequency preferences could be carefully
investigated to make a novel mechanobiology-based therapy more specific and effective
and mechanical forces should also be applied with a finely tuned manner.
Chapter 4 will provide specific guidance that may be utilized in the development
of a clinical mechanotherapy approach with maximum therapeutic efficacy.
Finally, chapter 5 will identify whether the vibratory stimulation could reverse the
fibrotic phenotype on scleroderma-derived fibroblasts through (1) downregulation of
TGF-β signaling, (2) attenuation of the gene expression of scleroderma phenotypic
targets, and (3) reduction of the increases in collagen synthesis and matrix stiffness in
SSc fibroblasts grown on polyurethane substrates.
In summary, fibrotic disease is commonly known as a progressive disorder with
permanent changes in organs and tissues that results from over-expressed pro-fibrotic
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cytokines and collagens. Although numerous types of antifibrotic therapies have been
investigated, none of the current strategies effectively achieve restoration of the matrix
composition and biomechanical properties of scarred tissue and organs. Therefore, these
studies will offer a basis for the design of a novel class of mechanotherapy
approach/device that may reverse the fibrotic phenotype in many fibrotic diseases and
comprise the first steps towards the development of vibratory mechanotherapy as a
clinical treatment for fibrotic disease.
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CHAPTER THREE
ANTIFIBROTIC EFFECTS OF VIBRATORY STIMULATION
ON HUMAN FIBROBLASTS
3.1. Abstract
Mechanical stimuli play a central role in regulating extracellular matrix
composition and organization during development, wound healing, and pathological
fibrosis. The superficial layer of the lamina propria (SLLP) in the human vocal folds
experiences a unique mechanical microenvironment of high frequency vibration during
voice production. The identification of macrophages and myofibroblasts in the SLLP of
healthy subjects suggests that the mechanical stresses imposed during routine speech
result in repetitive microtrauma, which is generally repaired without permanent
alterations in matrix composition or vocal quality. However, the mechanisms regulating
fibroblast matrix remodeling in the SLLP have not been fully elucidated. Here we show
that vibration downregulates transforming growth factor (TGF)-β signaling and inhibits
the induction of collagen synthesis by fibrotic stimuli in human fibroblasts.
Transcriptomic and protein-based assays revealed that vibration strongly induced the
expression of the profibrotic cytokines TGFB1, TGFB2, connective tissue growth factor
(CTGF), and endothelin-1 (EDN1). However, vibration also significantly affected the
TGF-β signaling pathway, with a net effect of antagonizing signal transduction through
reduced expression of TGF-β receptors and Smad signal transduction molecules and
increased expression of SMAD7, ubiquitin ligases, and transcriptional repressors
responsible for signaling inhibition. Vibration also inhibited cyclic strain- and TGF-β1-
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mediated collagen accumulation and mechanical stiffening of fibroblast-seeded 3D,
porous sponges, as well as reducing collagen content and mechanical stiffness of
fibroblast-seeded sponges previously cultured under cyclic strain. These results suggest
that vibration may offer the basis for development of a mechanomodulatory approach for
the treatment of a wide range of fibrotic disorders.
3.2. Introduction
Tissues and organs contain a stromal component composed primarily of
mesenchymally-derived cells and their secreted extracellular matrix (ECM) that provides
structural and biomechanical support for parenchymal cells. The ECM is a dynamic
structure that undergoes continuous remodeling through tightly regulated and coordinated
processes of protein synthesis and proteolytic degradation [313]. Fibrosis results from
pathological changes in the regulation of ECM remodeling, leading to excessive matrix
accumulation that eventually compromises tissue function [16,86]. Although the
molecular basis of fibrosis is not yet fully understood, cytokines and the mechanical
microenvironment are recognized as important regulators of ECM remodeling [314,315].
Transforming growth factor (TGF)-β1, TGF-β2, connective tissue growth factor (CTGF),
and endothelin 1 (EDN1) are profibrotic cytokines that stimulate ECM synthesis and are
chronically over-expressed in a variety of fibrotic diseases [316]. Mechanical factors,
including both changes in matrix stiffness and application of external loads, can also
influence matrix remodeling [317]. While many antifibrotic strategies seek to reduce
cytokine expression levels and signaling activity [318], relatively few studies have
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investigated the potential of mechanical factors for therapeutic modulation of matrix
remodeling.
The vocal fold lamina propria is a laryngeal connective tissue that is unique in
terms of its matrix composition and biomechanical function. Residing between a
squamous epithelium and the thyroaretenoid muscle, the lamina propria develops from a
relatively homogeneous tissue in newborns to a highly organized, layered anatomical
structure in adolescents [292,319]. The superficial layer of the lamina propria (SLLP) is
composed of reticular fibers, amorphous forms of elastin, hyaluronic acid, and
proteoglycans, while the intermediate and deep layers are enriched in mature elastic and
collagen fibers, respectively [280,282,320]. During phonation, the SLLP vibrates at
frequencies ranging from 100-300 Hz and amplitudes up to 1 mm, while the vocal
ligament, comprising the intermediate and deep layers of the lamina propria, undergoes
cyclic strain at lower (1-10 Hz) frequency [288]. Histological analysis has shown that
macrophages and myofibroblasts are consistently present in the vocal folds of healthy
subjects and concentrated in the SLLP [284,293,299]. On the basis of these observations,
it has been proposed that normal phonation results in repetitive microtrauma that is
routinely repaired without permanent changes in matrix composition or adverse effects
on vocal quality (18). However, the underlying mechanisms responsible for this healing
capacity remain unknown.
One of the fundamental principles of mechanobiology that has been demonstrated
across a wide variety of cell types is that physiologically-relevant mechanical loading
stimulates tissue-specific matrix gene expression [321–323]. The limited amount of
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mature fibrous ECM in the native SLLP suggests that exposure to high frequency
vibration may inhibit fibroblast expression and synthesis of fibrous matrix and offer a
basis for novel antifibrotic therapies. Recently, mechanical bioreactors have been used to
investigate vibration-induced changes in matrix-related gene expression in vitro. Despite
substantial variations in cell type, substrate, bioreactor design, and vibration protocol,
many studies have reported increased expression of genes consistent with the native
tissue physiology and potentially providing resistance to scarring, including up-regulation
of hyaluronic acid synthases, proteoglycans, and matrix metalloproteinase 1 (MMP1) and
no significant change or down-regulation of type I collagen [324–329]. One limitation of
these studies is that they have primarily relied upon RT-PCR analysis of a limited number
of targets and revealed little about the signaling pathways responsible for the effects
observed.
Here, we have performed a comprehensive analysis of the transcriptional response
of human dermal fibroblasts to high frequency vibration. While exposure to vibration
significantly increases expression of profibrotic cytokines, it simultaneously decreases
expression of fibrous collagens and inhibits the TGF-β signaling pathway. Using cyclic
strain and exogenous TGF-β1 as fibrotic models, we show that vibration counteracts
collagen accumulation and mechanical stiffening observed in a wide range of fibrotic
diseases.
3.3. Materials and Methods
3.3.1. Vibratory bioreactor
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The vibratory bioreactor module consisted of a modified T-75 flask as a culture
module and a bioreactor platform equipped with an electromagnetic voice coil actuator
(BEI Kimco, Vista, CA) and a stepper motor (PKK 244-02BA, Oriental Motor, Charlotte,
NC) constructed as previously described [322]. The voice coil actuator was connected to
a horizontal plastic tube holding 4 plastic rods that passed through flexible gaskets into
the interior of the flask upon which one end of each of 4 samples was mounted. The voice
coil actuator was driven by a sine wave from a frequency generator (4040A, B&K
Precision, Yorba Linda, CA) processed through a 10W amplifier (CK003, Cana Kit,
North Vancouver, Canada) and connected through a reed switch to the collector terminal
(+5 V from a PC) of a NPN transistor, the base terminal of which was connected to the
output from a custom LabVIEW program (National Instruments, Austin, TX) running on
a PC. On the other side of each bioreactor platform, a stepper motor was mounted and
connected by a pulley to a lead screw controlling the movement of an actuation bar
mounted on a linear slide assembly with 4 attached sample holding bars that passed into
the flask module. The stepper motor was controlled through stepper motor drivers (G201,
Geckodrive, Tustin, CA) and a 4-axis motion control card (DMC-18x2, Galil, Rocklin,
CA). The vibration and cyclic strain regimes were controlled by a custom LabVIEW
program. Porous, 3D sponges were fabricated from the elastomeric polyurethane
(Tecoflex®

SG-80A,

Lubrizol

Corporation,

Wickliffe,

separation/precipitation method as previously described [325].
3.3.2. Substrate strain measurement
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To calculate the actual substrate strains occurring within polyurethane sponges
during vibration, eight small dots of 0.7% Sudan Black B in two parallel rows were
placed on the surface of samples (25 mm in length x 5 mm in width x 2 mm in height) as
fiducial markers. During vibration, the oscillatory displacement of the substrate was
recorded using a Sony Handycam Camcorder (HDR-CX360) under a digital stroboscope
at a 1 Hz frequency offset. Images corresponding to both positions of neutral and
maximum sample displacement were extracted and substrate strains were determined by
measuring the initial and final separation distances between markers oriented parallel and
perpendicular to the direction of vibratory oscillation using Photoshop.
3.3.3. Cell culture
Adult normal human dermal fibroblasts (NHDFs; Lonza, Allendale, NJ) were
cultured in tissue culture flasks (Greiner Bio-one, Monroe, NC) with Dulbecco’s
Modification of Eagle’s Medium/Ham’s F-12 50/50 Mixture with L-glutamine
(DMEM/F12; Mediatech, Herndon, VA) supplemented with 10% v/v bovine growth
serum (BGS; Hyclone, Logan, UT) and 1% penicillin-streptomycin (Mediatech). Adult
human aortic adventitial fibroblasts (AoAF; Lonza) and adult normal human lung
fibroblasts (NHLF; kindly donated by Dr. Carol Feghali-Bostwick, Medical University of
South Carolina) were cultured in tissue culture flasks with Dulbecco's Modification of
Eagle's Medium (DMEM; Mediatech) supplemented with 10% v/v fetal bovine serum
(FBS; Hyclone) and 1% penicillin-streptomycin. Medium was changed every 3 days and
cells were passaged at a 1:3 ratio for expansion.
3.3.4. Bioreactor culture for microarray, qRT-PCR, and protein analysis
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1.2 x 106 NHDF between fourth and sixth passages were seeded on each 3D,
porous polyurethane sponge (25 mm in length x 5 mm in width x 2 mm in height)
mounted on a polyester frame and cultured in a 100 mm Petri dish containing
DMEM/F12 with 10% BGS and 1% penicillin-streptomycin for 4 days under static
conditions. The experimental group was subjected to a one-time 20% axial strain to
ensure the samples were all under approximately equal initial tension followed by
vibration at 100 Hz frequency, 3.8 Vrms, 1.28 ± 0.07 mm amplitude (“1X Strain +
Vibration”). Two control groups were used, one loaded in bioreactors and exposed to the
initial tensioning strain only (“1X Strain”) and another maintained under completely
static conditions (“Static”).
3.3.5. Microarray analysis
After 6 hours culture under vibratory or control conditions, total RNA was
immediately isolated by Trizol extraction followed by purification using the Qiagen
RNeasy Mini Kit (Qiagen, Valencia, CA) according to manufacturer’s protocols. Total
RNA samples were evaluated for quality using an Agilent Bioanalyzer 2100 (Agilent
Technologies, Palo Alto, CA). Total RNA samples were converted to fragmented, biotinlabeled cRNA using the GeneChip 3' IVT Express Kit (Affymetrix, Santa Clara, CA) and
then hybridized to Human PrimeView microarrays (Affymetrix) according to
manufacturer recommendations. Probe set expression values were extracted and
normalized by RMA algorithm using Expression Console software (Affymetrix). To
identify gene differentially expressed between the 1X Strain + Vibration samples and 1X
Strain samples, we employed a statistical test (Student’s t-test, unpaired, 2-tailed, not
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assuming equal variance) as well as a fold change threshold. The combination of these
two tests allows detection of statistically significant differences that had magnitude
changes that could be validated by other conventional mRNA measurement methods.
Comparative gene expression was conducted with dChip software [330]. Student’s t-test
and fold change thresholds were evaluated through empirical testing to find values that
satisfied two outcomes: 1) estimated false discovery for the group of genes identified as
differentially expressed would be ≤ 5%; 2) the group of genes identified would be of
sufficient size to permit functional enrichment analysis. Criteria that satisfied these
conditions were absolute fold change ≥ 2 and P < 0.05. The false discovery rate estimated
for these criteria, based on iterative permuted comparisons involving randomized sample
groupings, was 0.0%. ECM component genes were collected based on the Gene Ontology
tag extracellular matrix component (GO:0044420); TGF-β signaling pathway genes were
collected based on KEGG pathway identification (hsa04350) and via manual assignment.
To identify genes differentially expressed within the ECM component group and TGF-β
signaling pathway group, we chose to apply only a statistical test (Student’s t-test,
unpaired, 2-tailed, not assuming equal variance). This was chosen because group sizes
were relatively small and thus multiple testing errors would be expected to be less
prevalent that in comparisons involving total microarray content. Additionally, this would
be less stringent and therefore more permissive for detecting genes within the groups that
were affected by vibration. Evaluation of differential expression analyses conducted at a
threshold of P < 0.05 revealed false discovery rates approximated 4.5% for differentially
expressed ECM component genes and 6.2% for TGF-β signaling pathway genes. Gene
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ontology enrichment and KEGG Pathway enrichment analyses were conducted with the
Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 tool
[331,332]; enrichment scores were considered significant at P < 0.05. Raw data (CEL
files) and normalized expression data produced through this microarray study are
deposited in the NCBI Gene Expression Omnibus (accession GSE68386).
Table 3.1. Primer sequences used in Real-time RT-PCR

3.3.6. qRT-PCR
After 0.25, 1, 3, and 7 day culture under experimental/control conditions
described above, total RNA was isolated by combining TRIzol reagent (Invitrogen) and
RNeasy Mini Kit (Qiagen) as described above. Two step real time RT-PCR was
performed using Retroscript kit (Ambion, Austin, TX), Quantitect SYBR green PCR kit
(Qiagen), and target-specific primers (Table 3.1) using a Rotor-Gene 3000 Real-Time
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Thermal Cycler (Qiagen). Relative gene expression levels were calculated using 2-ΔΔCt
method with beta-2-microglobulin (B2M) as an internal standard [333]. For the 0.25 day
time point, n = 8 total samples were analyzed (n = 4 from the samples used for
microarray analysis and n = 4 from an independent replicate).
3.3.7. ELISA assay
Bioreactor flask modules were modified with plastic inserts to create an
individual compartment for each sample. NHDF seeded in 3D, porous polyurethane
sponges were cultured under experimental/control conditions described above and culture
medium samples collected at 1, 3, and 7 days. The concentration of connective tissue
growth factor (CTGF) secreted into the culture medium was determined using a sandwich
ELISA kit (Antigenix America, Huntington Station, NY). Ninety-six well high protein
binding ELISA plates (Greiner Bio-one) were coated with 2.0 mg/ml anti-CTGF capture
antibody overnight at room temperature. Plates were washed three times with PBS
containing 0.05% Tween 20 (PBST) and blocked with a 1% BSA solution for 2 h at room
temperature. One hundred microliter aliquots of CTGF standards or samples were added
to wells and incubated for 2 h at room temperature. After washing, 100 ml of 0.1 mg/ml
biotin labeled anti-CTGF detection antibody was added to wells and incubated at room
temperature for 2 h. Plates were again washed and 100 ml of 0.15 mg/ml peroxidaseconjugated streptavidin was added to each well, incubated at room temperature for 30
min, and washed. Following the addition of 100 ml aliquots of fluorogenic substrate, the
absorbance was measured at 390 nm using a microplate reader (Biotek Instruments,
Winooski, VT). The concentration of TGF-β1 (RayBiotech, Norcross, GA), TGF-β2
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(R&D Systems, Minneapolis, MN), and endothelin-1 (R&D Systems) were also
determined using a sandwich ELISA process according to manufacturer’s instructions.
For analysis of TGF-β1 and TGF-β2, media samples were activated for 10 min by
acidification using 1 N HCl followed by neutralization using 1.2 N NaOH/0.5 M HEPES.
3.3.8. Western blot analysis; TGF-β signaling
NHDF seeded in 3D, porous polyurethane sponges were cultured under
experimental/control conditions as described above. At 1, 3, and 7 days, sponges were
collected, washed three times with PBS, and lysed using RIPA lysis buffer (150 mM Tris
base (pH 7.6), 150 mM NaCl, 1% sodium deoxycholate, 0.1% SDS, and 1% Triton X100) supplemented with proteinase inhibitor cocktail (cOmplete™, Roche, Mannheim,
Germany) and phosphatase inhibitor cocktail (PhosSTOP™, Roche). Total protein
concentration in the lysates was measured by BCA assay (Pierce, Rockford, IL). Samples
(20 mg) were electrophoretically separated on SDS−polyacrylamide gel (10-17%) and
transferred to a PVDF membrane (Millipore, Bedford, MA, U.S.A.). Membranes were
soaked in 5% skim milk in Tris-buffered saline containing 0.05% Tween 20 (TTBS) for 2
h (except for the detection of phosphorylated proteins which was incubated in 5% horse
serum in TTBS overnight at 4 °C) to block nonspecific binding. Membranes were
incubated overnight at 4 °C with primary antibodies against SMAD3 (04-1035, EMD
Millipore, Chicago, IL), phospho-SMAD3 (07-1389, EMD Millipore), SMAD7 (ST1625,
Calbiochem), transforming growth factor b receptor 1 (TGFBR1) (06-1086, EMD
Millipore), TGFBR2 (06-227, EMD Millipore), TGFBR3 (MABC710, EMD Millipore),
salt-induced kinase 1 (SIK1) (ABE799, EMD Millipore), SKIL/SnoN (07-077, EMD
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Millipore), or beta-2-microglobulin (B2M) (ab75853, Abcam, Cambridge, MA), washed
three times with TTBS, and then incubated again with appropriate secondary antibodies
conjugated to horseradish peroxidase (Bio-Rad, Hercules, CA) for 50 min at room
temperature. Blots were developed using the Clarity™ Western ECL substrate (Bio-Rad)
following the manufacturer’s protocols. Luminescence was captured using a GS-690
imaging system (Bio-Rad) and densitometric analysis was performed with ImageJ
software. Quantitative data normalized to B2M densitometry levels are expressed as
mean ± standard deviation (SD) (Fig. 3.5).
3.3.9. In vitro fibrotic models
In order to model fibrotic conditions by stimulating collagen synthesis and
mechanical stiffening, NHDF, AoAF, and NHLF were seeded in 3D, porous
polyurethane sponges (1.2 x 106 cells/sponge) and initially cultured for 4 days under
static conditions as described above. Cells were exposed to pro-fibrotic conditions
(exogenous TGF-β1 supplementation or cyclic strain) either with or without simultaneous
application of vibratory stimulation. Once samples were transferred to bioreactors, all
groups including controls were supplemented with 1 mM L-ascorbic acid 2-phosphate
(Sigma) to support functional collagen deposition. For the TGF-β1 model, NHDF-seeded
sponges were subjected to a one-time 20% static strain and then cultured under static or
vibratory loading (100 Hz, 1.28 ± 0.07 mm amplitude) with and without 10 ng/ml
recombinant human TGF-β1 (PeproTech, Rocky Hill, NJ) for 6 h/day. For the cyclic
strain model, NHDF-, AoAF-, and NHLF-seeded sponges were subjected to a one time,
15% static strain (3 mm strain amplitude) for initial tensioning, followed by 5% axial
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cyclic strain (1 mm strain amplitude, 0.25 Hz) alone or in combination with vibration
under tension (100 Hz, 1.28 ± 0.07 mm amplitude, 3.05 s on/0.95 s off) for 8 h/day. The
vibratory ‘off’ period was required for stretch and relaxation during each strain cycle,
while the 8 hour total time maintained 6 hours total active vibration, consistent with all
previous studies. For the final set of studies to test whether vibratory stimulation could
promote the remodeling of the newly synthesized matrix, NHDF-seeded 3D, porous
polyurethane sponges were cultured under cyclic strain (5%, 0.25 Hz) for one week and
then subjected to a one-time 15% static strain followed by either static or vibratory (100
Hz, 1.28 ± 0.07 mm amplitude for 6 h/day) culture for an additional week.
3.3.10. Hydroxyproline assay
Collagen accumulation was quantified by the hydroxyproline assay as previously
described [334]. Briefly, polyurethane sponges were digested in 1 ml of 12 N HCl and
then hydrolyzed at 98 °C for 3 hours. After centrifugation, 20 µl aliquots of standards (4hydroxyproline, 0–400 µg/ml) and samples were transferred to a 96 well plate, then dried
in a vacuum oven overnight. Samples were mixed with 100 µl of chloramine T solution
[141 mg/ml chloramine-T, 1 ml n-propanol and 8 ml OH-Pro buffer (1.25 g citric acid, 3
g sodium acetate, 0.6 g NaOH, dissolved in 30 ml distilled water containing 0.3 ml
glacial acetic acid and 7.5 ml n-propanol, pH 6)]. Samples were mixed with 100 µl pdimethyl amino benzaldehyde solution (0.75 g p-dimethyl amino benzaldehyde in 3 ml npropanol and 1.3 ml 70% v/v perchloric acid), incubated for 20 min at room temperature,
and heated to 60 °C for 15 min. The absorbance was measured at 558 nm. Total collagen
content was calculated based on the estimation that hydroxyproline comprises about
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13.5% of the total collagen. Total collagen values were normalized to total DNA values
measured by using a PicoGreen assay (Molecular Probes, Eugene, OR). All chemicals
and solvents used in this study were purchased from Sigma-Aldrich and of analytical
reagent grade.
3.3.11. Tensile testing
NHDF-seeded samples were washed with PBS and cut free from the plastic
frames. The width and thickness of samples were measured using digital calipers.
Samples were mounted using rough-surfaced aluminum grips and set to a 5 mm
separation distance. The samples were strained to failure at 1 mm/s using an MTS
Synergie 100 (MTS Systems Corporation, Eden Prairie, MN) and data analyzed using
Testworks 4 software (MTS Systems Corporation). Construct elastic modulus was
calculated by a peak slope method, generally corresponding to the 30% to 60% strain
region as previously described [231].
3.3.12. Statistical analysis
Data analysis was done by using GraphPad Prism software (GraphPad, San
Diego, CA). Significant differences between groups were determined with one-way
analysis of variance (ANOVA) followed by Tukey multiple pairwise comparison tests. P
< 0.001 was accepted as statistically significant. All quantitative data are presented as
mean ± standard deviation (SD).
3.4. Results
3.4.1. Vibration elicits differential gene expression in human dermal fibroblasts
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To examine the transcriptional response caused by vibratory mechanical
stimulation, normal adult human dermal fibroblasts (NHDF) were cultured in 3D, porous
polyurethane sponges and loaded in a vibratory bioreactor as previously described [324].
The experimental group was subjected to a one-time 20% axial strain to ensure the
samples were all under approximately equal initial tension followed by vibration at 100
Hz and 1.28 ± 0.07 mm amplitude (“1X Strain + Vibration”). Measurements of the
displacement of fiduciary markers during vibration indicated that this mechanical
stimulus produced corresponding substrate strains of 0.25 ± 0.09% and 1.65 ± 0.23%
parallel and perpendicular to the axis of oscillatory motion, respectively. Two control
groups were used, one loaded in bioreactors and exposed to the initial tensioning strain
only (“1X Strain”) and another maintained under completely static conditions (“Static”).
After 6 h culture, total RNA samples were collected and subjected to microarray analysis.
Findings indicated that vibratory stimulation caused significant changes in gene
expression (P < 0.05 and fold change > 2), with 778 genes up-regulated and 557
significantly down-regulated in 1X Strain + Vibration samples compared to 1X Strain
samples (Fig. 3.1A). Expression patterns revealed that many of these genes were
influenced by vibration in a manner that was independent of axial strain, i.e., these genes
showed no overt response to 1X Strain relative to the Static condition (Fig. 3.1A, genes
highlighted by black bars). However, other genes responded to vibration in a manner that
resembled either an augmentation or a reversal of the response to 1X Strain relative to the
Static condition (Fig. 3.1A, genes highlighted by white bars). Although the static
condition was included as a baseline reference, all subsequent analyses focused on
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differences between the 1X Strain + Vibration and 1X Strain groups to identify changes
solely attributable to the effect of vibration.

Figure 3.1. Vibration stimulates differential gene expression including ECM and TGF-β
signaling components. (A) Global analysis of all transcripts represented on the
microarrays detected 1335 differentially expressed genes (P < 0.05 and fold change > 2)
affected by 1X Strain + Vibration compared to 1X Strain groups. Analyses of ECM (B)
and TGF-β signaling pathway components (C) identified 110 (27.2%) and 92 (36.9%)
genes significantly affected (P < 0.05) by 1X Strain + Vibration relative to 1X Strain,
respectively. The black bars on the right side of heat maps represent gene clusters that
were solely influenced by vibration, while the white bars represent genes that responded
to vibration as well as strain. n = 3 independent samples per group.
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Biological pathways (KEGG, Kyoto Encyclopedia of Genes and Genomes) and
biological processes (GO, Gene Ontology) that were significantly affected by 1X Strain +
Vibration relative to 1X Strain are summarized in Table 3.2 and 3.3, respectively.
Vibration responsive genes were enriched for a variety of growth factor signaling
pathways, notably including the TGF-β pathway (Table 3.2). Consistent with the broad
changes in gene expression elicited by vibration, RNA polymerase II dependent
transcription was one of the most significantly enriched biological process categories.
Also of note were multiple processes relating to tissue repair including regulation of cell
proliferation, regulation of cell migration, angiogenesis, and response to wounding (Table
3.3).
Table 3.2. Biological pathways significantly enriched in NHDFs subjected to 1X Strain +
Vibration relative to 1X Strain.
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Table 3.3. Biological processes significantly enriched in NHDFs subjected to 1X Strain +
Vibration relative to 1X Strain.

Given the established connections between mechanical stimulation and ECM
remodeling and the fact that the TGF-β pathway is prominently involved in matrix
regulation, we performed new analyses of the microarray data that focused on genes
encoding ECM components and TGF-β signaling molecules. Of the 405 ECM component
genes represented on the microarray, 110 (27.2%) were significantly affected by 1X
Strain + Vibration relative to 1X Strain (P < 0.05; Fig. 3.1B), confirming that vibration
exerts a substantial influence on ECM gene expression. Similarly, 92 of 249 of genes
related to the TGF-β signaling pathway (36.9 %) were significantly affected by 1X Strain
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+ Vibration compared to the 1X Strain group (P < 0.05), including those involved in both
BMP/activin and TGF-β/Smad signaling (Fig. 3.1C).

Figure 3.2. Vibration significantly affects mRNA expression levels of genes associated
with matrix remodeling. *Fold change (FC) values are displayed for selected target genes
encoding cytokines, fibrous collagens and regulators of matrix turnover, and components
of the TGF-β signaling pathway exhibiting significant differences (P < 0.05) in mRNA
expression levels in response to 1X Strain + Vibration relative to 1X Strain group (n = 3
independent samples per target). Target abbreviations are color-coded to identify genes
involved in stimulating (red) and inhibiting (green) fibrous matrix deposition and TGF-β
signal transduction. †P value enrichment score calculated by the Database for Annotation,
Visualization and Integrated Discovery (DAVID). ‡Check marks identify targets
displaying a change in expression considered indicative of an antifibrotic effect (AF)
defined as increased expression of targets that inhibit matrix deposition and TGF-β signal
transduction and decreased expression of targets that stimulate matrix deposition and
TGF-β signal transduction.
Figure 3.2 summarizes genes related to matrix remodeling (cytokines, ECMs, and
TGF-β/Smad signaling pathway components) showing significant changes (P < 0.05) in
expression levels in response to vibration. Interestingly, profibrotic cytokines (TGFB1,
TGFB2, CTGF, and EDN1) were up-regulated, while fibrous collagens were downregulated. Among numerous components of the TGF-β signaling pathway showing
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differential expression, the majority of changes favored an antifibrotic effect defined as
down-regulation of genes that promote TGF-β signal transduction and up-regulation of
those involved in signaling inhibition/termination. Overall, these results suggest that
while vibratory simulation increases the expression of profibrotic cytokines, it
simultaneously modulates signaling pathways to inhibit their activity.
3.4.2. Vibration increases expression of profibrotic cytokines, but not fibrous collagens
qRT-PCR and ELISA assays were performed to validate the microarray results
for cytokine and collagen expression at the 6 hour (0.25 day) time point and investigate if
these changes were sustained when vibration was applied for 6 h/day for 1, 3 and 7 days.
With respect to 1X Strain controls, qRT-PCR results confirmed that vibration resulted in
significant increases in expression of profibrotic cytokines TGFB1, TGFB2, CTGF, and
EDN1 at all time points with the exceptions of TGFB1 at 0.25 days and EDN1 at 7 days
(Fig. 3.3A). mRNA expression levels of collagens COL1A1, COL3A1, and COL5A2 in
fibroblasts exposed to vibration were either significantly lower or not significantly
different from 1X Strain controls at all time points (Fig. 3.3B). In contrast, expression of
the collagenase MMP1 was significantly increased at Days 0.25, 3, and 7. Because
increases in profibrotic cytokine gene expression did not result in increased collagen
expression as would normally be expected, ELISA assays were performed to confirm that
increases in cytokine mRNA resulted in increased protein expression. Consistent with the
mRNA results, protein levels of TGFB1, TGFB2, CTGF and EDN1 were significantly
higher in vibrated samples relative to 1X Strain controls at 1 and 3 days and for TGFB1
at 7 days, although protein levels for all cytokines except TGFB1 significantly decreased
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between day 1 and 7 (Fig. 3.3C). Collectively, these results suggest that vibration
interferes with the induction of collagen matrix expression that normally results from
increased expression of profibrotic cytokines.

Figure 3.3. Vibration increases expression of profibrotic cytokines, but not fibrous
collagens. Relative mRNA expression levels of profibrotic cytokines (A) and fibrous
collagens (B). All data were normalized to static control at 0.25 days. n = 8 for 0.25 day
time point and n = 4 for 1, 3, and 7 day time points. (C) Soluble protein concentrations of
profibrotic cytokines released in the culture medium measured by ELISA assay. n = 4
samples per group. *(P < 0.001) compared with 1X Strain group at the same time point,
†
(P < 0.001) compared with 1X Strain + Vibration group at 0.25 day time point. All bar
graphs, mean ± SD.
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3.4.3. Vibration negatively regulates the TGF-β signaling pathway
To investigate the possibility that down-regulation of TGF-β signaling observed
in vibrated samples might block collagen induction despite increased expression of
profibrotic cytokines, we further investigated the expression levels of TGF-β receptors,
Smad signaling intermediaries, ubiquitin ligases involved in receptor degradation (Smad
specific E3 ubiquitin protein ligase (SMURF)1, SMURF2, and salt-inducible kinase 1
(SIK1)), and the nuclear transcriptional regulator SKI-like proto-oncogene (SKIL) by
qRT-PCR and Western blotting after 0.25, 1, 3, and 7 days of vibratory culture. Among
targets that facilitate TGF-β signal transduction, mRNA expression levels of TGF-β
receptor type II (TGFBR2), TGFBR3 and SMAD3 were significantly reduced in vibrated
samples relative to 1X Strain controls at all time points with the exception of TGFBR2 at
3 days (Fig. 3.4A).
In contrast, mRNA expression levels of targets involved in signaling inhibition
(SMAD7, SMURF1, SIK1, and SKIL) were significantly up-regulated at all time points
and SMURF2 at day 3 and 7 relative to 1X Strain controls (Fig. 3.4B). Western blot
analysis also confirmed down-regulation of signal transduction molecules and upregulation of signaling inhibitors (Fig. 3.4C, quantification of densitometry provided in
Fig. 3.5). In general, changes in expression observed at day 1 became more pronounced
at 3 and 7 days, most notably with expression of all three TGF-β receptors dropping to
almost undetectable levels by day 7. These results suggest that inhibition of TGF-β
signaling through a combination of reduced expression of receptors/signal transduction
molecules and induction of negative feedback/inhibitory pathways is one mechanism by
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which vibration inhibits induction of collagen synthesis despite elevated expression of
profibrotic cytokines.

Figure 3.4. Vibration inhibits TGF-β signaling through down-regulation of targets
involved in signal reception/transduction and up-regulation of signaling inhibitors.
Relative mRNA expression levels of targets involved in TGF-β signal transduction (A)
and inhibition (B). All data were normalized to static control at 0.25 days. All bar graphs,
mean ± SD. n = 8 for 0.25 h time point and n = 4 for 1, 3, and 7 day time points. *(P <
0.001). (C) Western blot analysis of TGFBR1, TGFBR2, TGFBR3, SMAD3,
phosphorylated Smad3 (pSMAD3), SMAD7, SIK1, SKIL and beta-2-microglobulin
(B2M) used as a control. n = 4 samples per group. *(P < 0.001) compared with 1X Strain
group at the same time point, †(P < 0.001) compared with 1X Strain + Vibration group at
0.25 day time point.
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Figure 3.5. Densitometric analysis of western blots. Protein expression (TGFBR1,
TGFBR2, TGFBR3, SMAD3, phosphorylated Smad3 (pSMAD3), SMAD7, SIK1, and
SKIL) was normalized based on the densitometry of beta-2-microglobulin (B2M) that
was used as an endogenous control. n = 3 independent experiments. *(P < 0.001)
compared with 1X Strain group at the same time point, †(P < 0.001) compared with 1X
Strain + Vibration group at 1 day time point. All bar graphs, mean ± SD.
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3.4.4. Vibration blocks collagen accumulation and mechanical stiffening in fibrotic
models in vitro
In order to demonstrate that the responses to vibration observed at the molecular
level may have functional significance in the context of wound healing and fibrotic
disease, the effects of vibration on fibroblasts were evaluated using two in vitro models
well-established to stimulate collagen synthesis and mechanical stiffening. In the first
model, NHDF-seeded sponges were cultured under static or vibratory conditions in the
presence of TGF-β1. Relative to untreated static controls, TGF-β1 stimulated significant
increases in collagen accumulation and stiffness in static samples. However, when
samples were cultured under vibratory conditions in the presence of TGF-β1, no
significant changes in either outcome were observed (Fig. 3.6A).
In the second model, cell-seeded samples were subjected to cyclic strain alone or
in combination with vibration. In order to test the broader applicability of vibratory
stimulation, these studies were performed with NHDF, human aortic adventitial
fibroblasts (AoAF), and human lung fibroblasts (NHLF). For all 3 fibroblast types,
samples cultured under cyclic strain exhibited significant increases in collagen and
stiffness relative to static controls, while samples cultured under cyclic strain in
combination with vibration did not (Fig. 3.6B). In the final set of studies, we asked if
exposure to vibration after previous culture under cyclic strain could promote remodeling
of the newly synthesized matrix. When NHDF-seeded sponges conditioned by cyclic
strain for one week were cultured an additional week under static conditions, significant
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increases in collagen and stiffness compared with one week cyclic strain or static
conditions were observed (Fig. 3.6C).

Figure 3.6. Vibration blocks collagen deposition and mechanical stiffening induced by
cyclic strain and exogenous TGF-β1. (A) NHDF seeded in 3D, porous polyurethane
sponges were subjected to a one-time 20% axial strain and then cultured under static and
vibratory conditions (100 Hz, 1.28 ± 0.07 mm amplitude for 6 h/day) with and without
exogenous TGF-β1 supplementation (10 ng/ml) for 7 days. (B) 3D, porous polyurethane
sponges seeded with NHDF, AoAF, and NHLF were cultured under static conditions,
cyclic strain alone (5%, 0.25 Hz), or cyclic strain in combination with vibration (100 Hz,
1.28 ± 0.07 mm amplitude, 3.05 s on/0.95 s off) for 8 h/day for 7 days. (C) NHDF-seeded
3D, porous polyurethane sponges were cultured under cyclic strain (5%, 0.25 Hz) for one
week and then subjected to a one-time 15% static strain followed by static or vibratory
(100 Hz, 1.28 ± 0.07 mm amplitude for 6 h/day) culture for an additional week. *(P <
0.001) compared with static culture without TGF-β1 (A) or static control (B and C), †(P <
0.001). All graphs, mean ± SD (n = 4).
In contrast, samples subjected to vibration during the second week exhibited
significant decreases in collagen and stiffness relative to the one week cyclic strain group,
reaching levels not significantly different from the one week static control. In order to
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ensure that vibration was not detrimental to the cells, cell number based on DNA content
was measured and found not to vary significantly among the groups in any of the three
models (Fig. 3.7). We believe these results demonstrate for the first time that high
frequency vibration can block critical events in the initiation and progression of fibrotic
disease and potentially reverse pathological matrix accumulation in the early stages of
disease.

Figure 3.7. Cell number per sponge assessed by DNA content. (A) NHDF seeded in 3D,
porous polyurethane sponges were subjected to a one-time 20% axial strain and then
cultured under static and vibratory conditions (100 Hz, 1.28 ± 0.07 mm amplitude for 6
h/day) with and without exogenous TGF-β1 supplementation (10 ng/ml) for 7 days. (B)
3D, porous polyurethane sponges seeded with NHDF, AoAF, and NHLF were cultured
under static conditions, cyclic strain alone (5%, 0.25 Hz), or cyclic strain in combination
with vibration (100 Hz, 1.28 ± 0.07 mm amplitude, 3.05 s on/0.95 s off) for 8 h/day for 7
days. (C) NHDF-seeded 3D, porous polyurethane sponges were cultured under cyclic
strain (5%, 0.25 Hz) for one week and then subjected to a one-time 15% static strain
followed by either static or vibratory (100 Hz, 1.28 ± 0.07 mm amplitude for 6 h/day)
culture for an additional week. All bar graphs, mean ± SD. ns, nonsignificant
3.5. Discussion
Connective tissue throughout the body experiences cyclic tensile loading during
routine locomotion at relatively low frequency (~≤ 1 Hz) and high magnitude (~ 5-10%
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strain). Stromal matrix, composed primarily of type I collagen, provides resistance to
these loads. In healthy tissue, fibroblasts balance new matrix synthesis and proteolytic
degradation to achieve tensional homeostasis [317]. Mechanobiology plays a central role
in maintaining this equilibrium. Numerous studies have shown that exposure to tension,
either externally applied or endogenously generated by culture within restrained gels or
on relatively stiff surfaces promotes matrix synthesis, while shielding from external loads
or exposure to highly compliant substrates accelerates matrix degradation [38,44,222].
One of the central mechanisms underlying this response is tension-induced increases in
both the expression and activation of TGF-β1 [335,336]. Particularly in the case of
collagen, interference with TGF-β1 activity or signaling has been shown to block tensioninduced increases in collagen expression [232]. CTGF expression has also both been
shown to be sensitive to mechanical tension, however, it is not always clear if this is
direct response or a consequence of strain-induced TGF-β1 expression, for which CTGF
is a prominent downstream target [337].
In the present study, we examined the transcriptional response to vibratory
stimulation, which, compared to most models of externally applied tension reported in the
literature, is characterized by relatively high frequency (100 Hz) and low strain (<1.65%
in this study). Although vibration caused significant and sustained increases in mRNA
and protein expression of profibrotic cytokines, expression levels of the major fibrillar
collagens implicated in fibrosis (Type I, III, and V) were not significantly affected even
after 7 day culture. While few previous studies have examined the effect of vibration on
cytokine expression, several have examined type I and III collagen expression and also
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observed no significant change or down-regulation [324,326–329]. One exception is the
study by Wolchok et al. that observed significant increases in TGFB1, CTGF, and
collagen type I, as well as increased mechanical stiffness of thin polyurethane foams,
however, the experimental design was substantially different since a circular sample
geometry was used with complete circumferential fixation and 2D culture for gene
expression studies [338]. Although the microarray study did not reveal differential
expression of any of the major collagenolytic proteases, we investigated MMP1
expression by qRT-PCR since it had previously been reported to be responsive to
vibration and found significant increases at several time points. The potential fibrotic
activity of the differential expression observed for TIMP2 and TIMP3 is unclear. While
TIMPs have historically been considered profibrotic due to their ability to inhibit
proteases that degrade matrix, recent studies have reported increased fibrosis in TIMP-2
and TIMP-3 knockout models, suggesting a more complex role for TIMPs than originally
thought [339]. Collectively, these results suggest that vibration exhibits potential
antifibrotic activity by inhibiting the induction of collagen gene expression normally
activated by profibrotic cytokines and potentially stimulating matrix degradation through
induction of MMP1.
Evaluation of TGF-β signaling pathway genes significantly affected by vibration
suggested a possible explanation for how profibrotic cytokine activity might be
suppressed. Among a wide range of gene targets involved in ligand binding, intracellular
signal transduction, transcriptional activation/repression, and negative feedback, an
overall pattern of changes in gene expression consistent with inhibition of TGF-β

89

signaling was observed. First, vibration negatively regulated ligand-receptor interactions
by significantly decreasing expression of TGFBR1 and TGFBR2, as well as TGFBR3
that binds TGF-β1 and TGF-β2 and increases their affinity for TGF-β receptor type II
[340]. Second, vibration reduced the potential for intracellular signal transduction by
decreasing expression of receptor-regulated Smads (R-Smads, SMAD2 and SMAD3) and
the Co-Smad, SMAD4. In addition, vibration increased expression of prostate
transmembrane protein, androgen induced 1 (PMEPA1), a cytoplasmic protein that can
bind and sequester both inactive and active R-Smads, and the inhibitory Smad, SMAD7,
which competes with R-Smads for binding to activated receptors [341,342]. Third,
vibration increased expression of ubiquitin ligases (SMURF1, SMURF2, and WWP1)
and SIK1 that down-regulate TGF-β signaling by targeting R-Smads and TGF-β receptor
type I for proteosomal degradation [139,343–345]. Finally, vibration down-regulated
expression of the transcriptional co-activator cAMP response element-binding protein 1
(CREBBP), while increasing expression of the transcriptional repressors Smad nuclear
interacting protein 1 (SNIP1) and SKIL [346–348]. Overall, these results suggest that
vibration down-regulates cellular capacity for TGF-β signal transduction.
TGF-β is considered a key player in the pathogenesis of multiple fibroproliferative disorders due to its overexpression in diseased tissue and ability to stimulate
both matrix synthesis and myofibroblast differentiation [24]. Although a variety of
strategies for inhibition of TGF-β activity have shown promise in animal models, success
in human clinical trials has been limited [349,350]. In addition, due to its multiple roles in
immunomodulation, tumor suppression, and wound healing, prolonged suppression of
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TGF-β activity to treat chronic disease may have detrimental side effects [24]. A
mechanically-based antifibrotic therapy could offer several substantial benefits relative to
existing pharmaceutical approaches, including localized/regional as opposed to systemic
activity and ease of dose adjustment and discontinuation that will likely offer improved
safety and reduced systemic side effects. As a first step towards establishing proof-ofconcept for high frequency vibration as a mechanomodulatory therapy, we showed that
vibration can inhibit collagen accumulation and mechanical stiffening in a 3D culture
model in response to exogenous TGF-β1 and cyclic strain as models of profibrotic
stimuli. While we have primarily focused on dermal fibroblasts since the skin is
vulnerable to several fibrotic disorders and the most easily accessible target for
mechanotherapy, the demonstration of similar responses in cardiac and lung fibroblasts
suggests vibration may have widespread application.

Several mechanically-based

therapies utilizing high frequency stimulation such as shock wave therapy, low intensity
pulsed ultrasound, and low magnitude, high frequency whole body vibration are reaching
clinical application [183,266,351]. Currently, these treatments are primarily focused on
increasing osteogenesis to promote bone healing and counteract osteoporosis and
accelerating angiogenesis to improve graft survival. To our knowledge, this is the first
study demonstrating the ability of high frequency mechanical stimulation to counteract
increased matrix synthesis in response to profibrotic stimuli.
3.6. Conclusion
In conclusion, these studies show that while vibration increases the expression of
profibrotic cytokines, it simultaneously modulates the expression of multiple components
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of the TGF-β signaling pathway with a net effect of inhibiting capacity for signal
transduction. When applied in combination with profibrotic stimuli, vibration inhibits
collagen synthesis and mechanical stiffening. This approach, while prophylactic, may
have clinical relevance to pathologies such as radiation-induced fibrosis. The ability of
vibration to reduce collagen and stiffness after prior exposure to cyclic strain, suggests
potential for intervention in the early stages of disease progression, although it is
important to acknowledge that the newly synthesized matrix induced by cyclic stain in
our model likely lacks the maturity, organization, and crosslinking of accumulated
collagen in clinical fibrosis. Another limitation of the present study is that while we have
focused on the fibroblast as the key effector cell in all fibrotic disorders, the complex,
multicellular pathology of fibrosis cannot be fully emulated by in vitro models. In order
to advance this work, future studies will further test the ability of vibration to reverse the
fibrotic phenotype of fibroblasts derived from patients with established disease such as
systemic sclerosis and idiopathic pulmonary fibrosis and evaluate its efficacy in animal
models of fibrotic disease.
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CHAPTER FOUR
THE EFFECT OF VARIABLE VIBRATORY PARAMETERS
ON FIBROBLAST MATRIX SYNTHESIS
4.1. Abstract
Mechanical stimuli are critical modulators of extracellular matrix (ECM)
synthesis and remodeling adhering to the structural and functional needs of the specific
tissues. Understanding of changes in ECM molecules by fibroblasts led by vibratory
mechanical forces provides how the vocal folds maintain and develop vocal fold-specific
matrices in response to vibratory stresses and strains. Fibroblast-seeded elastomeric
substrates were housed in vibratory bioreactors and cultured under various vibrational
parameters including amplitude, frequency, and duration. Overall, vibratory mechanical
stimulation exhibited a significant alteration in the mRNA expressions of vocal foldrelated ECM molecules and cytokines regulating ECM metabolism. The gene expression
of HA synthase 1 (HAS1), HA synthase 2 (HAS2), hyaluronidase 2 (HYAL2), TIMP3,
TGFB2, CTGF, and endothelin-1 (EDN1) was significantly increased, whereas COL1A1
and COL3A1 were significantly suppressed, suggesting that the expression profiles of
genes induced by vibration are similar to physiologically relevant vocal fold ECM
composition. Interestingly, our results show that the mRNA expression patterns are
significantly responsive to increasing doses of vibrational loadings and altered by
different levels of amplitudes or frequencies. These studies demonstrated that vibration
can stimulate the tissue-specific mRNA expression to support the vocal fold
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microenvironment and will provide specific guidance for the development of a clinical
mechanotherapy approaches in the context of vocal fold wound healing and regeneration.
4.2. Introduction
Cells constantly experience dynamic mechanical loads, including compression,
shear stress, tensile strain, hydrostatic pressure, and interstitial fluid flow. Through
various mechanotransduction processes, these stimuli activate intracellular signaling
pathways that influence many aspects of cell behavior including proliferation,
differentiation, extracellular matrix (ECM) deposition, soluble factor production, and
tissue development [352]. One of the seminal discoveries in mechanobiology has been
the ability of physiologically-relevant mechanical stimulation to activate tissue-specific
matrix gene expression. For example, dynamic compression promotes the synthesis of
sulfated glycosaminoglycans (S-GAG) and improves the growth and mechanical
properties of cartilaginous tissues [323]. Cyclic strain stimulates collagen expression and
synthesis in cardiac, mesangial, periodontal, pulmonary, tendon, and ligament fibroblasts
and elastin synthesis in smooth muscle cells [231,321,353]. These forms of relatively
high amplitude, low frequency stimulation have been widely applied in bioreactor
systems to increase the mechanical properties in engineered tissues. Alternatively,
relatively low amplitude, high frequency mechanical stimulation in the form of whole
body vibration (WBV) [354,355], low-intensity pulsed ultrasound (LIPUS) [356,357],
and extracorporeal shock wave [258,259,358] have been used clinically to improve both
bone and soft tissue healing. However the underlying mechanisms responsible for these
effects are not well understood.
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The vocal folds are unique laryngeal connective tissues that routinely experiences
high frequency vibration during voice production [324]. Several characteristics of the
superficial layer of the lamina propria (LPs) within the vocal folds and its relation to the
vibratory microenvironment have potential relevance to wound healing. First, the ECM
of the native LPs contains relatively high levels of GAGs/proteoglycans (hyaluronan,
versican, decorin, and fibromodulin), many with anti-scarring activity, and relatively low
levels of fibrous matrix proteins including collagen and elastin. Histological
identification of macrophages and myofibroblasts in the LPs of healthy subjects suggests
that normal phonation causes LPs microtrauma that is repaired without substantial
alterations in matrix composition. Several recent studies have shown that vibration
regulates fibroblast expression of many genes encoding matrix constituents relevant to
LPs physiology, including upregulation of hyaluronan synthase 1 (HAS1) and HAS2 in
human laryngeal fibroblasts [324,327] and increased expression of HAS3 in human
neonatal foreskin fibroblasts [329], but reduced expression of collagen type I [325,329].
In addition, we have recently shown that high frequency vibration is able to inhibit the
TGF-β signaling pathway and block cyclic strain- and TGF-β-mediated collagen
accumulation and mechanical stiffening. Therefore, further understanding of the
mechanisms of vibratory mechanotransduction may offer the opportunity to development
mechanotherapies capable of modulating wound healing and preventing fibrosis.
Despite the clinical success of mechanotherapies, a commonly cited weakness is
the limited information available with respect to optimal parameters and doses of
treatment [359,360]. Several studies suggest that a mechanical stimulus is composed of
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multiple parameters that induce different levels of molecular and cellular responses
[231,358,361]. Specifically, the effect of cyclic tension variables such as strain, pulse
shape, and pulse frequency has been reported among different cells types and
experimental designs [231,361]. Tranquillo et al. have investigated the effect of different
regimes of cyclic strain on collagen expression of smooth muscle cells (SMCs) and found
that each of the parameters affected the levels of elastin and collagen production and
mechanical strengthening of collagen constructs compared to statically cultured controls
[361]. Joshi and Webb also examined dose-dependent responses of cell/scaffold stiffness
in response to variable cyclic strain amplitude, rate, frequency, and duration, and
observed significant differences in mechanical properties [231]. In addition, shock waves
are defined by multiple parameters including the number of impulses, the frequency of
impulses, and the density of energy fluxes. Many clinical studies have been conducted to
better characterize and optimize the shock wave therapies in numerous groups of wounds
[358]. Thus, an improved understanding of the relationship between the characteristics of
applied vibratory loading and resulting cellular responses is an important consideration in
the development of a vibratory mechanotherapy.
Vibration can be described by three principle characteristics (frequency,
amplitude, and duration) [324]. Biomechanically, vocal fold mucosa experiences the
vibration at high frequency (100–200 Hz) and deforms approximately 1 mm laterally
during each vibration cycle. Vocalization times can vary between ~ 1-2 hrs per day for
normal voice user, while heavy voice users like classroom teachers and opera singers can
speak for ~ 6-7 h per day [325,362]. In addition, the normal phonatory cycle consists of

96

alternating periods of vibration and rest and vocal tissues normally receive a long rest
period each day during sleep. In this study, we characterized the effect of systematically
varying these vibratory loading characteristics (frequency, amplitude, and duration) on
ECM-related gene expression in human dermal fibroblasts.
4.3. Materials and Methods
4.3.1. Fabrication of elastomeric sponges
Porous polyurethane sponges were fabricated as previously described [363].
Briefly, Tecoflex SG-80A (4.05 gm; Lubrizol Corporation, Wickliffe, OH) was dissolved
in dimethylacetamide (39.1 ml; EMD Millipore, Billerica, MA) overnight at 70 °C.
Pluronic 10R5 (18.95 ml; BASF, Florham Park, NJ) was slowly added and the polymer
solution was then stirred for 4 hours. The temperature was slowly lowered to 56 °C and
the phase-separated mixture was pipetted into delrin molds (3 mm deep x 10 mm wide x
100 mm length). The molds were immediately transferred to a cold ethanol bath, cooled
for 2 minutes, and then submerged in distilled water overnight to precipitate the Tecoflex
sponge and remove the Pluronic. The substrates were removed from molds, stirred gently
in distilled water for 3 days with five additional water changes to completely remove any
remaining solvents/Pluronic, and then lyophilized for 3 days.
4.3.2 Vibratory bioreactor
The vibratory bioreactor module consisting of a bioreactor platform equipped
with an electromagnetic voice coil actuator (BEI Kimco, Vista, CA) and a modified T-75
flask was constructed as previously described [324]. A sinusoidal waveform signal from
a frequency generator (4040A, B&K Precision, Yorba Linda, CA) was processed through
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a 10W amplifier (CK003, Cana Kit, North Vancouver, Canada), and transmitted to the
input terminal of a reed switch connected to the voice coil actuator. The reed switch was
connected to a collector terminal (+5 V from a PC) of a NPN transistor, the base terminal
of which was connected to the output port from a custom Labview program (National
Instruments, Austin, TX) running on a PC. The vertical displacement of the voice coil
was translated into horizontal displacement of a plastic tube holding 4 plastic rods that
passed through flexible gaskets into the interior of the T75 flask upon which one end of
each sample was mounted. The other end of each sample was mounted on a fixed support
pin on the other side of the flask. The frequency and magnitude of the sine-wave
oscillation were controlled by the function generator. Total duration, active vibration
intervals (‘on’ and ‘off’ times), and inactive (rest) time per day were controlled by the
custom Labview software program (National Instruments).
4.3.3. Fibroblast seeding in porous tecoflex sponges
Porous polyurethane substrates (25 mm in length × 3 mm in thickness × 5 mm in
width) mounted on a polyester frame using a UV curable adhesive (Loctite 3311) were
sterilized by immersion in 70% ethanol for 15 min and washing three times with sterile
distilled water, then incubated overnight in 20 µg/ml fibronectin (Sigma, St. Louis, MO)
in Dulbecco’s phosphate-buffered saline (PBS). For cell seeding, fibronectin-coated
polyurethane substrates were suspended on the two delrin support bars and incubated at
37 oC for 30 minutes. Adult normal human dermal fibroblasts (NHDFs, Lonza, Allendale,
NJ) at passages fifth and sixth were trypsinized and re-suspended at 1 x 107 cells/ml. Two
20 µl aliquots of cell suspension were seeded on the top surface of each substrate,
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incubated 30 min at 37 °C, and then the samples were turned over and seeded on the
opposite side in an identical manner. After 30 min, this procedure was repeated once
more with a second seeding onto the top of the substrate, leading to a final seeding
density of 1.2 x 106 cells/substrate. The substrates were placed in a 100 mm Petri dish
containing DMEM/F12 media (Mediatech, Herndon, VA) with 10% BGS (Hyclone,
Logan, UT) and 1% penicillin-streptomycin (Mediatech) and cultured for 4 days.
Table 4.1. Variable vibration regimes characterized by varying amplitude, frequency, and
duration

4.3.4. Vibratory culture
After 4 days of static incubation, NHDF-seeded polyurethane substrates were
transferred to the vibratory bioreactor. For vibratory culture, the substrates (n = 4 per
group) were subjected to a one-time 20% axial strain and cultured under various
vibratory regimes, while control samples were subjected to a one-time 20% axial strain
followed by static cultured or maintained under static conditions. The specific parameters
that were investigated in this study are shown at Table 4.1. In general, each parameter
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was individually varied while the others were held constant using our standard vibration
regime (3.8 Vrms, 100 Hz, 6 h) as a baseline. The displacements of porous polyurethane
substrates at the driving point were measured at the frequency of 25-125 Hz and the
voltage of 1.9, 3.8, and 4.6 Vrms using a digital stroboscope (Fig. 4.1).

Figure 4.1. Displacement of porous polyurethane substrates in the vibratory bioreactor.
The substrate displacement was measured at the driving point of polyurethane substrates
vibrating at variable frequency (25−125 Hz) and variable voltage (1.9−4.6 Vrms) using a
digital stroboscope.
4.3.5. mRNA expression analysis
After vibratory culture, the samples (n = 4) were immediately minced in 1 mL
TRIzol reagent (Thermo Fisher Scientific, Waltham, MA), homogenized, and centrifuged
at 14,825 rcf for 15 min at 4 ºC. After centrifugation, 0.2 mL chloroform (Acro Organics,
Morris Plains, NJ) was added to the supernatant previously transferred to a
microcentrifuge tube, and the mixture was agitated, incubated for 10 min, and centrifuged
at 14,825 rcf for 15 min at 4 ºC. Subsequently, total RNA was isolated from the aqueous
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phase using RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s
instructions. The quality and quantity of isolated total RNA were determined using a
Take3 Micro-volume plate (BioTek Instruments, Winooski, VT) and a microplate reader
(BioTek Instruments, Winooski, VT). 1 µg of total RNA from each sample was used to
synthesize cDNA using RETROscript kit (Thermo Fisher Scientific) according to the
manufacturer’s protocol. Real-time RT-PCR was performed with Quantitect SYBR green
PCR Kit (Qiagen) using custom-designed sense and anti-sense primers (Table 4.2) in a
Rotorgene 5000 thermal cycler (Qiagen). Relative expression levels of target genes were
quantified by the 2–ΔΔCt method, using beta-2-microglobulin (B2M) as an internal
standard [364] and expressed as relative fold changes compared to the static control
group.
Table 4.2. Primer sequences use in Real-time RT-PCR
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4.3.6. Statistical analysis
For the studies to determine the effects of vibratory stimulation with variable
amplitude, frequency, and ‘on/off’ time cycle on fibroblast ECM expression, statistical
multiple comparisons were performed using a modified Tukey-Kramer method for
unequal-sized groups, particularly between 1X Strain and other experimental groups. For
the studies to identify whether ECM expression in response to vibratory stimulation is
dose-dependent and loading-specific response, one-way analysis of variance (ANOVA)
followed by Tukey's post hoc test was used for statistical analysis with multiple
comparisons. P values less than 0.05 were considered significant. All quantitative data
are expressed as mean ± standard deviation.
4.4. Results
4.4.1. Effect of variable amplitude on fibroblast ECM expression
Fibroblast-seeded porous sponges were cultured under static, one-time 20%
strain, or one-time 20% strain and vibratory loading with different amplitudes generated
by varying the voltage applied to the voice coil actuator. mRNA expression levels of
HAS1, HAS2, HYAL2, TIMP3, TGFB2, CTGF, and EDN1 were significantly upregulated in response to vibration at all amplitudes and MMP1 at the highest amplitude
only compared to the 1X Strain control (Fig. 4.2). COL1A1 was significantly upregulated at the lowest amplitude only, while COL3A1 was significantly decreased at the
two higher amplitudes. When expression levels were compared between variable
amplitude groups, the gene expression of HAS1, HAS2, MMP1, TIMP3, TGFB2, CTGF,
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and EDN1 were significantly increased at the highest vibratory amplitude, while
COL1A1 and COL3A1 were significantly reduced at the highest vibratory amplitude.

Figure 4.2. Relative mRNA expression levels of various matrix proteins, matrix
remodeling enzymes, and profibrotic cytokines in response to either 1X Strain or 1X
Strain + Vibration with variable voltage (1.9−4.6 Vrms) and fixed frequency (100 Hz)
relative to static control. n = 3 samples per group. *(P < 0.05) compared with 1X Strain
group, †(P < 0.05) statistical comparisons among variable vibration groups. All bar
graphs, mean ± SD.
4.4.2. Effect of variable frequency on fibroblast ECM expression
Since vibratory frequency and amplitude are inter-dependent, in order to account
for this, two variable frequency studies were performed: one in which the voltage was
adjusted to compensate and maintain constant amplitude at varying frequencies and
another one in which amplitude was allowed to change alongside frequency. When the
substrates were cultured under variable frequency vibration with constant amplitude, a
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significant up-regulation of HAS1, HYAL2, TIMP3, CTGF and EDN1 were observed in
response to vibration at all frequencies relative to 1X Strain control (Fig. 4.3).

Figure 4.3. Relative mRNA expression levels of various matrix proteins, matrix
remodeling enzymes, and profibrotic cytokines in response to either 1X Strain or 1X
Strain + Vibration with fixed amplitude (approximately 1.28 ± 0.07 mm in amplitude)
defined by variable frequency (25−100 Hz) and variable voltage (1.5−3.8 Vrms) relative
to static control. n = 3 samples per group. *(P < 0.05) compared with 1X Strain group,
†
(P < 0.05) statistical comparisons among variable vibration groups. All bar graphs, mean
± SD.
mRNA expression levels of HAS2 were significantly increased at the two highest
frequencies and TGFB2 at the highest frequency only compared to the 1X Strain control.
COL1A1 and COL3A1 were significantly decreased at all frequencies compared with 1X
Strain control. When expression levels were compared between variable frequency
groups, gene expression of HAS2, TIMP3, TGFB2, CTGF, and EDN1 were significantly
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increased at the highest vibratory frequency, while HAS1 was significantly elevated at
the lowest vibratory frequency. No significant differences in mRNA expression levels of
COL1A1, COL3A1, and MMP1 were not observed in response to variable vibratory
frequency groups.

Figure 4.4. Relative mRNA expression levels of various matrix proteins, matrix
remodeling enzymes, and profibrotic cytokines in response to either 1X Strain or 1X
Strain + Vibration with variable amplitude (0.64−1.98 mm in amplitude) defined by
variable frequency (25−100 Hz) and fixed voltage (3.8 Vrms) relative to static control. n
= 3 samples per group. *(P < 0.05) compared with 1X Strain group, †(P < 0.05) statistical
comparisons among variable vibration groups. All bar graphs, mean ± SD.
In the second variable frequency study in which amplitude was allowed to freely
change, mRNA expression levels of HAS1, HAS2, HYAL2, TIMP3, TGFB2, CTGF, and
EDN1 were significantly increased in response to vibration at all frequencies and MMP1
at 50 Hz frequency only compared to the 1X Strain control (Fig. 4.4). In addition,
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COL1A1 was significantly elevated at the lowest frequency and reduced at the highest
frequency compared to 1X Strain control. COL3A1 was also significantly decreased at all
frequencies. When expression levels were compared between variable frequency groups,
significant increases in mRNA expression levels of TGFB2 and EDN1 were observed at
the highest frequency, while HAS2, COL1A1, and CTGF were significantly higher at the
lowest frequency.
4.4.3. Effect of variable total duration on fibroblast ECM expression
To investigate the effect of vibration exposure time on gene expression,
fibroblast-seeded sponges were exposed to vibration for 2, 4, and 6 h. Moreover, since we
applied 1X tension at the time of substrate loading, additional groups, 1X Strain group (2,
4, and 6 h) were included in order to clearly observe the effect of vibratory stimulation
alone. We found that there was no significant differential gene expression induced by
one-time 15% tensioning at all time point compared to static control, except for MMP1 at
2 h, TGFB2 at 6 h, and CTGF and EDN1 at the 2 and 4 h time point (Fig. 4.5).
Interestingly, however, mRNA levels of all targets induced by 1X Strain were returned to
the levels that were not significantly different to those of statically cultured group except
for TGFB2. Relative to 1X Strain controls, vibration leads to a significant increase in the
mRNA expression levels of HAS1, HYAL2, CTGF and EDN1 at all time points and
HAS2, MMP1, TIMP3, and TGFB2 at the two highest time points. However, COL1A1 at
2 and 6 h and COL3A1 at 4 and 6 h were significantly decreased. When the mRNA levels
were compared among varying time duration groups, HAS1, CTGF, and EDN1 notably
exhibited the highest expression levels at the 2 h time point. Other targets including
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HAS2, HYAL2, MMP1, TIMP3, and TGFB2 showed significantly higher expression
levels at the 4 and 6 h time points relative to the 2 h time point.

Figure 4.5. Relative mRNA expression levels of various matrix proteins, matrix
remodeling enzymes, and profibrotic cytokines in response to either Static, 1X Strain, or
1X Strain + Vibration with variable duration (2, 4, and 6 hours) at fixed frequency (100
Hz) and fixed voltage (3.8 Vrms) relative to static control. n = 3 samples per group. *(P <
0.05) compared with 1X control at each time point, †(P < 0.05) ) statistical comparisons
among variable vibration groups. All bar graphs, mean ± SD.
4.4.4. Effect of variable active/rest (ON/OFF) periods on fibroblast ECM expression
The normal phonatory cycle consists of repetitive vibration and rest periods. To
evaluate the effect of varying active/rest periods of vibratory patterns on ECM-related
gene expresison, the substrates were cultured under three different time cycles
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(vibrated/non-vibrated, ON/OFF, sec/sec): 2/4, 4/2, and 6/0 (constant) for total 6 h. The
results demonstrated that the mRNA expression levels induced by vibratory stimulation is
dose-dependent. The vibratory patterns with different time periods exhibited a significant
increase in HAS1 and CTGF in response to vibration at all cycle patterns, while mRNA
expression levels of HAS2, HYAL2, TIMP3, TGFB2, and EDN1 were significantly upregulated at the two higher dosing cycles and MMP1 at the two lower dosing cycles (Fig.
4.6).

Figure 4.6. Relative mRNA expression levels of various matrix proteins, matrix
remodeling enzymes, and profibrotic cytokines in response to either 1X Strain or 1X
Strain + Vibration with variable time cycle (e.g. 2 second on/4 second off in total 6 sec
(2s/4s), 4s/2s, and 6s/0s) at fixed frequency (100 Hz) and fixed voltage (3.8 Vrms)
relative to static control. n = 3 samples per group. *(P < 0.05) compared with 1X Strain
group, †(P < 0.05) statistical comparisons among variable vibration groups. All bar
graphs, mean ± SD.

108

However, a significant down-regulation in COL1A1 at the highest and lowest
dosing cycles and COL3A1 at the two lower dosing cycles were observed in response to
vibration relative to 1X Strain control. When expression levels were compared between
variable vibratory time cycle groups, mRNA expression levels of HAS2, HYAL2,
TIMP3, TGFB2, CTGF, and EDN1 were significantly increased with increasing total
vibration, while MMP1 was significantly reduced with increased total vibration.
Expression of COL1A1 and COL3A1 were either not significantly different or
significantly lower than 1X strain control under all vibratory conditions.
4.4.5. Changes in gene expression after discontinuation of vibration and re-exposure
Lastly, we tested whether the changes in gene expression elicited by vibration
were a transient or long-lasting response. In addition to 1X strain control and vibration
for 6 h, two additional groups were added: (a) 6 h vibration followed by 18 h rest period
and (b) 6 h vibratory culture for 3 days. Significant changes in gene expression levels
were observed when mRNA expression levels were compared between 6 h vibrated and 6
h vibration followed by further 18 h static culture (Fig 4.7). HAS1, HAS2, HYAL2,
MMP1, TIMP3, TGFB2, CTGF, and EDN1 were significantly downregulated at, by more
that 7-folds, 2-folds, 5-folds, 0.5-folds, 2-folds, 9-folds, 5-folds, and 9-folds, compared
with 6 h vibration groups, respectively. By contrast, COL1A and COL3A1 were
significantly up-regulated after 6 h vibration followed by 18 h static culture, by
approximately 2-folds, compared with 6 h vibration groups. In addition, when the
substrates seeded with fibroblasts were vibrated for 6 h per day up to 3 days, we found
that the mRNA expression levels of HAS1, HAS2, TIMP3, and CTGF were significantly
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increased at day 3 compared with one day 6 h vibration group, while the levels of
HYAL2, MMP1, TGFB2, and EDN1 mRNAs remained up-regulated at day 3, although
not significantly different compared to one day 6 h vibration group. Moreover, the levels
of COL1A1 and COL3A1 remained significantly downregulated under vibratory culture
over 3 days.

Figure 4.7. Transient response of vibratory stimulation on the gene expression of various
matrix proteins, matrix remodeling enzymes, and profibrotic cytokines, but responsive to
vibration (6 h/day) for 3 days. Relative mRNA expression levels of various matrix
proteins, matrix remodeling enzymes, and profibrotic cytokines in response to Vibration
(6 h), Vibration (6 h) followed by resting period (18 h), or Vibration (6 h/day) for 3 days
at fixed frequency (100 Hz) and fixed voltage (3.8 Vrms) relative to static control. n = 3
samples per group. *(P < 0.05) compared with static control, †(P < 0.05) statistical
comparisons between 6 h vibration and 6 h vibration + 18 h resting or between 6 h
vibration at one day or at 3 days. All bar graphs, mean ± SD.
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4.5. Discussion
Mechanical cues are critical in maintaining and developing the microenvironment
of living cells and tissues, and the cellular and molecular responses to mechanical stimuli
has been widely investigated for induction of tissue-specific matrix synthesis. In this
study, using an in vitro vibratory bioreactor, we cultured human dermal fibroblasts under
variable vibratory patterns defined by three main characteristics (amplitude, frequency,
and duration) and then analyzed the molecular response to vibratory stimulation through
the mRNA analysis of ECM-related and cytokine genes. The objective was to gain
fundamental insight into the sensitivity of changes in gene expression to changes in
vibratory stimulus and determine if it was possible to identify a particular component of
the vibratory pattern that had the strongest influence on gene expression.
With regard to tissue-specific matrix production in response to vibratory
stimulation, several studies have focused on differential expression of vocal fold ECMrelated genes by human laryngeal and dermal fibroblasts in response to vibratory
mechanical stimuli using different bioreactor modules [324,329,338]. Titze et al.
investigated the effects of physiologically relevant vibratory stimulation on gene
expression by human laryngeal fibroblasts cultured in porous Tecoflex sponges. They
showed that vibratory stimulation at 100 Hz for 6 h resulted in a significant increase in
fibronectin, MMP-1, and HA synthase 2 (HAS2) compared with those of statically
cultured fibroblasts [365]. Farran et al. cultured human neonatal foreskin fibroblasts
(NFFs)-seeded silicon membrane under vibratory stimulation at the range of 60−300 Hz
with the varying displacement (1–30 µm) for 1 h followed by a 6 h rest. They found that
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the gene expression of collagen type I was not significantly elevated at high frequency (≥
100 Hz), while vibration at below 60 Hz led to a significant increase in collagen type I
expression compared with static controls. However, the gene expression of HAS3 and
HYAL1 at increased displacement was significantly increased relative to those at lower
range of displacements (≤ 5 um). In addition, vibratory stimulation at the frequency of
110 Hz and displacement of 30 mm led to 0.8-folds and 0.9-folds decreases in the mRNA
levels of collagen type 1 and MMP1 compared to the static controls, respectively.
Regarding collagen expression, they also reported that lower frequency with decreased
amplitude induced elevated collagen type I expression. Moreover, NFF cultured under
vibration at 110 Hz with a displacement of 30 mm for 1 h resulted in 20% reduction in
collagen type I expression compared to the static culture [329]. Kutty and Webb also
subjected human dermal fibroblasts to a vibration (100 Hz in frequency and 5.3 Vrms in
voltage) in a 2s/2s (ON/OFF) regimen for 4 h per day over 7 days. They also found that
HAS2 and MMP1 expression were significantly increased, while did not lead to
significant changes in collagen expression [325].
In a similar manner, our results also demonstrated that vibratory stimulation
induced the mRNA expression of vocal fold-specific ECM molecules and cytokines
regulating ECM metabolism including HAS1, HAS2, HYAL2, TIMP3, TGFB2, CTGF,
and EDN1, whereas COL1A1 and COL3A1 were suppressed. Interestingly, the gene
expression of HAS1, HAS2, TIMP3, TGFB2, CTGF, and EDN1 was extremely sensitive
to vibratory stimulation, however, the profiles of HYAL2, COL1, COL3A1, and MMP1
were less responsive to vibratory stimulation. Our results also suggest that the molecules
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that were responsible for regulating matrix degradation and remodeling can also be
modulated by vibration stimulations. Interestingly, MMP1 and TIMP3 look more
sensitive to frequency and amplitude changes. In addition, it is suggested that vibratory
forces should be applied with a precisely timed manner. Because, a significant change in
mRNA expression induced by 6 h of vibratory stimulation cannot be observed after 18 h
of resting period after vibratory culture.
As a therapeutic application of vibratory stimulation, this study investigated for
the first time the effects of variable vibratory regimes on ECM gene expression and
provided a basis how the vibratory stimulation could be formed and shaped to be
effective for vocal fold tissue regeneration. Although there are experimental limitations
that our vibratory module cannot fully produce more broad range of frequency that
correspond to physiological levels (100-300 Hz), our results indicates that high frequency
vibration can positively modulate the gene expression of vocal fold ECM against the
molecular response of vocal fold injury through increasing HASs and decreasing
collagens. Ultimately, the optimal vibratory amplitude and dosing will need to be tested
in an animal model.
4.6. Conclusions
Variable vibratory loading regimes induced different levels of ECM-related gene
expression in human dermal fibroblasts. HAS1, HAS2, HYAL2, TGFB2, CTGF, and
EDN1 exhibited strong sensitivity to changes in vibratory amplitude and duration, while
COL1A1 and COL3A1 did not seem to be responsive to vibratory stimulation. The
altered mRNA expressions by vibratory stimulation demonstrated by this study are
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consistent with ECM composition that is physiologically relevant to vocal fold mucosa:
increased HA-related molecules and decreased collagens, despite unexpected induction of
cytokines. To be more clinically effective vibratory mechanotherapy against wound
healing, we acknowledge that more specific parameters finely-tuned by amplitude,
frequency, and duration need to be carefully considered, however, we believe that this
study may provide a basic guideline for a potential vibratory therapy in the context of
wound healing. The future studies will further test the ability of variable vibration
regimes to optimize the induction of tissue-specific ECM production.
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CHAPTER FIVE
ATTENUATION OF THE FIBROTIC PHENOTYPE OF SCLERODERMA DERMAL
FIBROBLASTS BY VIBRATORY STIMULATION: POTENT ANTIFIBROTIC
MECHANOTHERAPY
5.1. Abstract
Fibrosis can lead to permanent functional loss in every major organ, accounting
for 45% of deaths in the United States. Recent studies suggest that mechanical forces
may be an important therapeutic target that is able to modulate ECM synthesis and
enhance wound healing. Previous studies have shown that vibration significantly downregulated TGF-β signaling and prevented collagen synthesis and accumulation.
Moreover, vibration blocked induction of collagen production and mechanical stiffening
of polyurethane substrates by profibrotic stimuli for a week. In this study, scleroderma
fibroblasts seeded in porous polyurethane sponges were subjected to either further static,
cyclic strain (0.25 Hz, 5% strain amplitude) or cyclic strain in combination with vibration
under tension (100 Hz frequency, 3.8 Vrms, 1.28 ± 0.07 mm amplitude). qRT-PCR
results show that vibration decreased pathological markers (TGFBR2, IL1A, IL4, FBN1,
IL1A, IL4, LOX1, TIMP1, COL1A1, and COL3A1 that are over-expressed by
scleroderma fibroblasts), and increased antifibrotic regulators (SMAD7 and FLI1)
compared with the cyclic strain alone group. In addition, vibration significantly reduced
total collagen content and substrate stiffness induced by cyclic strain condition. These
studies suggest that vibration may be applicable as a novel mechanotherapy approach for
treatment of fibrotic diseases in multiple tissues and organs.
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5.2. Introduction
Systemic sclerosis (SSc) is a systemic, connective-tissue disease that eventually
leads to pathologic fibrosis in the skin and numerous internal organs. Fibrosis in dermal
tissue manifests as the excessive, progressive deposition of collagens and other
extracellular matrix (ECM) components due to the aberrant expression of transforming
growth factor (TGF)-β accompanied by a severe fibroproliferative vasculopathy and
immune system abnormality [119,120,366,367]. Fibroblasts derived from clinically
affected skin areas of patients with scleroderma exhibit activated phenotypic markers
with aberrant expression of cytokines and growth factors and massive production of
extracellular matrix components including Interleukin 1 (IL1) [368], IL4 [369], IL6
[370], connective tissue growth factor (CTGF) [371], endothelin 1 (EDN1) [372],
Cartilage
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Protein

(COMP)

[373],

tissue

inhibitors

of

metalloproteinases (TIMPs) [374], Fibrillin 1 (FBN1) [375], lysyl oxidase (LOX) [376],
and collagens (COL) [374]. Although a variety of strategies against fibrotic disorders
have targeted the increased expression of profibrotic cytokines, specifically TGF-β and
its downstream molecules which are known to promote collagen synthesis and
myofibroblast activation [377–380], success in clinical treatments has been restricted
[381].
In addition to soluble signaling factors, mechanical forces have been shown to be
able to modulate cytokine and ECM synthesis and secretion in the context of wound
healing [37,266,354,355,382,383]. For example, shockwaves are known to promote
wound healing through suppressed expression of the pro-inflammatory cytokines such as
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IL-1, IL-6, and TNF-α [258]. Several clinical studies also demonstrated that vibration
(30–50 Hz) leads to enhanced wound healing by elevated expression of angiogenic
factors (VEGF and IGF1) and transition to myofibroblasts with less inflammatory
phenotype [384–387]. An increased wound healing was also reported when vibration
generated by Vibro-Pulse therapy (Vibrant Medical, Sheffield) applied locally to the
wound site [388]. Previously, we have shown that vibratory stimulation may offer a
potential mechanotherapy for fibrotic diseases. Human dermal fibroblast-seeded
polyurethane substrates subjected to cyclic strain (0.25 Hz) in combination with vibration
(100 Hz, 1.28 ± 0.07 mm amplitude) exhibited reduced collagen accumulation and
mechanical stiffening of the substrates compared with those cultured under cyclic strain
(0.25 Hz) alone. Vibration also significantly inhibited collagen deposition and substrate
stiffening induced by exogenous addition of TGF-β. We noted that vibration downregulated TGF-β signaling via decreased expression of signal transduction molecules
(TGFBR2, TGFBR3, and SMAD3) and increased expression of molecules involved in
signal inhibition (SMAD7, SMURF1, SMURF2, SIK1, and SKIL).
The purpose of this study was to investigate the antifibrotic effects of vibratory
stimulation on scleroderma (SSc) fibroblasts. Here we show that vibratory stimulation (1)
induces downregulation of TGF-β signaling in SSc fibroblasts consistent with our
previous study in normal fibroblasts, (2) attenuates the expression of scleroderma
phenotypic targets, and (3) reduces the increases in collagen accumulation and substrate
stiffening by SSc fibroblasts-seeded in polyurethane sponges subjected to cyclic strain.
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5.3. Materials and Methods
5.3.1. Polyurethane sponge fabrication
Porous polyurethane sponges were fabricated as previously described [363].
Briefly, Tecoflex SG-80A (4.05 gm; Lubrizol Corporation, Wickliffe, OH) was dissolved
in dimethylacetamide (39.1 ml; EMD Millipore, Billerica, MA) overnight at 70 °C.
Pluronic 10R5 (18.95 ml; BASF, Florham Park, NJ) was slowly added to Tecoflex
solution and the polymer solution was then stirred for additional 4 hours. The temperature
was slowly lowered to 56 °C and the cloudy mixture was pipetted into delrin molds (100
mm in length × 10 mm in width × 3 mm in depth). The molds were immediately
transferred to a cold ethanol bath, cooled for 2 minutes, and then soaked in distilled water
overnight to precipitate the Tecoflex sponge and remove the Pluronic. After 24 h, the
polyurethane sponges were removed from molds, washed with distilled water for 2 days
to completely remove any remaining solvents/Pluronic, and then lyophilized.
5.3.2. Scleroderma dermal fibroblast culture
Porous polyurethane substrates (25 mm in length × 5 mm in width × 2 mm in
height) mounted on a polyester frame using a UV curable adhesive (Loctite 3311) were
sterilized by 70% ethanol for 15 min and washed three times with sterile distilled water,
then incubated overnight in 20 µg/ml fibronectin (Sigma, St. Louis, MO) in phosphatebuffered saline (PBS) at 4 oC with constant mild stirring. For cell seeding, fibronectincoated polyurethane sponges were suspended on two delrin support bars and incubated at
37 oC for 30 minutes. Human dermal fibroblasts from clinically affected (“SSc”) and
clinically unaffected areas (“Normal”) of patients with scleroderma (SSc) were kindly

118

donated by Dr. Carol A. Feghali-Bostwick (Medical University of South Carolina). Both
normal and SSc dermal fibroblasts were cultured and expanded in Dulbecco’s modified
Eagle’s medium (DMEM; Mediatech, Herndon, VA) supplemented with 10% fetal
bovine serum (FBS; Hyclone, Logan, UT) and 1% penicillin-streptomycin (Mediatech).
Both fibroblasts at passages between fourth and sixth were trypsinized and re-suspended
at 1 x 107 cells/ml. Two 20 µl aliquots of cell suspension were seeded on the top surface
of each substrate, incubated 20 min at 37 °C, and then re-seeded on the opposite side in
an identical manner. After another 20 min, this procedure was repeated again for the top
of the substrate, leading to a final seeding density of 1.2 x 106 cells per substrate. The
substrates were placed in a T75 flask containing DMEM/F12 media (Mediatech,
Herndon, VA) with 10% BGS (Hyclone, Logan, UT) and 1% penicillin-streptomycin
(Mediatech) and cultured for 4 days.
5.3.3. Vibratory culture
The vibratory bioreactor module consisted of a bioreactor platform equipped with
an electromagnetic voice coil actuator (BEI Kimco, Vista, CA) and a modified T-75 flask
as previously described [324]. A sinusoidal waveform signal coming from a frequency
generator (4040A, B&K Precision, Yorba Linda, CA) was processed through a 10W
amplifier (CK003, Cana Kit, North Vancouver, Canada), and then transmitted to the input
terminal of a reed switch connected to the voice coil actuator. The reed switch was
connected to a collector terminal (+5 V from a PC) of a NPN transistor and the base
terminal of which was connected to the output port from a custom LabView program
(National Instruments, Austin, TX) running on a PC. The vertical movement produced by
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voice coil actuator was transformed into horizontal displacement that allows to vibrate 4
polyurethane sponges at the same time. The frequency and magnitude of the sine-wave
oscillation were controlled by the function generator and total duration controlled by the
custom LabView software program (National Instruments). For vibratory culture,
fibroblast-seeded polyurethane sponges were transferred to the vibratory bioreactor after
4 days of static incubation. The samples (n = 4 per group) were subjected to a one-time
20% axial strain and cultured under vibration (100 Hz, 1.28 ± 0.07 mm amplitude for 6
h/day), while control samples were maintained under static conditions.
5.3.4. In vitro fibrotic model
In order to model the fibrotic phenotype by stimulating collagen synthesis and
mechanical stiffening, scleroderma fibroblast-seeded in porous polyurethane sponges (1.2
x 106 cells per sponge) were subjected to profibrotic conditions (cyclic strain) either with
or without simultaneous application of vibratory stimulation. Briefly, once the samples
were transferred into the vibratory bioreactor, samples were exposed to a one time, 15%
static strain (3 mm strain amplitude) for initial tensioning, followed by 5% axial cyclic
strain (1 mm strain amplitude, 0.25 Hz) alone or in combination with vibration under
tension (100 Hz, 1.28 ± 0.07 mm amplitude, 3.05 s on/0.95 s off) for 8 h/day, as
described in section 3.3.9. All samples including controls were cultured in DMEM/F12
media (Mediatech) supplemented with 10% BGS (Hyclone), 1% penicillin-streptomycin
(Mediatech), and particularly with 1 mM L-ascorbic acid 2-phosphate (Sigma) to support
functional collagen deposition [8].
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Table 5.1. Primer sequences used in Real-time RT-PCR

5.3.5. Quantitative RT-PCR analysis
Following vibratory culture, the samples (n = 4) were immediately minced in 1
mL TRIzol reagent (Thermo Fisher Scientific, Waltham, MA), homogenized, and
centrifuged at 14,825 rcf for 15 min at 4 ºC. After centrifugation, 0.2 mL chloroform
(Acro Organics, Morris Plains, NJ) was added to the supernatant solution previously
isolated, and the mixture was then vigorously agitated, incubated for 3 min, and
centrifuged at 14,825 rcf for 15 min at 4 ºC. Subsequently, total RNA was isolated from
the aqueous phase using RNeasy Mini Kit (Qiagen, Valencia, CA) according to
manufacturer’s instructions. The quality and quantity of isolated total RNA were
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determined using a microplate reader (BioTek Instruments, Winooski, VT) equipped with
a Take3 Micro-volume plate (BioTek Instruments). 1 mg of total RNA from each sample
was used to synthesize cDNA using RETROscript kit (Thermo Fisher Scientific)
according to the manufacturer’s protocol. Real-time RT-PCR was performed with
Quantitect SYBR green PCR Kit (Qiagen) using custom-designed sense and anti-sense
primers (Table 5.1) in a Rotorgene 5000 thermal cycler (Qiagen). Relative expression
levels of target genes were normalized by the 2–ΔΔCt method using beta-2-microglobulin
(B2M) as an internal standard [364] and expressed as relative fold changes compared to
the controls.
5.3.6. Hydroxyproline assay
Collagen accumulation was measured by the hydroxyproline assay modified from
the original method described by Woessner et al. [334]. Briefly, polyurethane sponges
following vibratory culture were digested in 1 ml of 12 N HCl, boiled at 98 °C for 3
hours, and cooled down to room temperature. After centrifugation, 20 µl aliquots of
samples and standard solutions (4-hydroxyproline) were transferred to a 96 well plate,
then dried in a vacuum oven overnight. Samples were dissolved in 100 µl of chloramine
T solution [141 mg/ml chloramine-T, 1 ml n-propanol and 8 ml OH-Pro buffer (1.25 g
citric acid, 3 g sodium acetate, 0.6 g NaOH, dissolved in 30 ml distilled water containing
0.3 ml glacial acetic acid and 7.5 ml n-propanol, pH 6.0)], mixed with 100 µl p-dimethyl
amino benzaldehyde solution (0.75 g p-dimethyl amino benzaldehyde in 3 ml n-propanol
and 1.3 ml 70% v/v perchloric acid), incubated for 20 min at room temperature, and then
heated to 60 °C for 15 min. The absorbance was measured at 558 nm using a microplate
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reader (BioTek Instruments). Total collagen content was calculated based on the
estimation that hydroxyproline comprises about 13.5% of the total collagen [389]. Total
collagen values were normalized to total DNA values quantified using a PicoGreen
dsDNA assay kit (Molecular Probes, Eugene, OR). All chemicals and solvents used in
this study were provided by Sigma-Aldrich and of analytical reagent grade.
5.3.7. Tensile testing
After vibratory culture, samples were gently washed with PBS and removed from
the plastic frames. The width and thickness of samples were measured using a digital
caliper. Samples were mounted using aluminum grips covered with Gator P100
sandpaper (Ali Industries, Inc., Fairborn, OH) to prevent slippage. The separation
distance between top and bottom grips was set to 5 mm. Using a 100 N load cell, the
samples were strained until failure at 1 mm/s using an MTS Synergie 100 (MTS Systems
Corporation, Eden Prairie, MN) and data analyzed using Testworks 4 software (MTS
Systems Corporation). Construct elastic modulus was calculated by a peak slope method,
generally corresponding to the 30% to 60% strain region as previously described [231].
5.3.8. Statistical Analysis
Data analysis was performed by using GraphPad Prism software (GraphPad, San
Diego, CA). One-way analysis of variance (ANOVA) with Tukey's post hoc was used for
statistical analysis of multiple comparisons. P values less than 0.05 were considered
significant. All quantitative data are expressed as mean ± standard deviation.
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5.4. Results
5.4.1. Vibration down-regulates mRNA expression of TGF-β signaling molecules in
scleroderma fibroblasts
We first characterized differences in expression of TGF-β-related genes between
non-lesional (normal) and lesional (SSc) fibroblasts in 1X Strain controls and then how
gene expression changed in response to 1X Strain + Vibration after 7 days in culture.
With respect to normal fibroblasts, qRT-PCR showed significantly increased expression
of the profibrotic cytokines TGFB1, CTGF, and EDN1 in SSc fibroblasts (Fig 5.1A). In
addition, consistent with previous studies, vibratory stimulation produced significant
increases in expression of CTGF and EDN1 compared with 1X Strain controls in both
normal and scleroderma fibroblasts and TGFB1 in SSc fibroblasts only. Expression levels
of TGFBR1, TGFBR2, and SMAD3, but not TGFBR3 were also significantly increased
in SSc relative to normal fibroblasts (Fig 5.1B). Exposure to vibration resulted in
significant decreases in TGFBR2 in SSc fibroblasts and TGFBR3 and SMAD3 in both
normal and SSc fibroblasts relative to 1X strain controls. Among three targets involved in
inhibition of TGF-β signaling, SMAD7 expression levels were significantly lower in SSc
than normal fibroblasts, while SIK1 and SKIL were not significantly different (Fig.
5.1C). However, exposure to vibration significantly increased expression of all three
targets in both cell types.
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Figure 5.1. Vibration down-regulates TGF-β signaling on SSc fibroblasts. Relative
mRNA expression levels of profibrotic cytokines (A) and downstream targets involved in
TGF-β signal transduction (B) and inhibition (C). All data were normalized to static
control at 7 days. n = 4 samples per group. *(P < 0.05) compared with normal dermal
fibroblast group (Normal), †(P < 0.05) compared with 1X Strain group in each cell. All
bar graphs, mean ± SD.
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Figure 5.2. Vibration prevents collagen synthesis and accumulation on SSc fibroblasts.
Relative mRNA expression levels of fibrous collagens relative to static control at day 7
(A), collagen content, substrate stiffness, and cell number (B). n = 4 samples per group.
*(P < 0.05) compared with normal dermal fibroblast group (Normal), †(P < 0.05)
compared with 1X Strain group in each cell; ns, nonsignificant. All bar graphs, mean ±
SD.
5.4.2. Vibration prevents collagen gene expression, matrix accumulation, and mechanical
stiffening by scleroderma fibroblasts
Dermal fibroblasts isolated from lesional skin of scleroderma patients are known
to overexpress collagen type I and III compared with those from clinically nonlesional
skin [390,391]. qRT-PCR results showed significantly elevated expression of collagens
COL1A1 and COL3A1 in SSc fibroblasts relative to normal fibroblasts (Fig. 5.2A). In
addition, expression levels of COL1A1 in both SSc and normal fibroblasts and COL3A1
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in SSc fibroblasts were significantly reduced by exposure to vibratory stimulation relative
to 1X Strain controls. Moreover, total collagen accumulation and mechanical stiffness
were significantly higher for SSc fibroblasts than normal fibroblasts under static or 1X
strain conditions (Fig. 5.2B). Collagen content and elastic modulus were both
significantly reduced in SSc-seeded samples exposed to vibration relative to static and 1X
strain conditions and not significantly different from levels observed in normal
fibroblasts. Cell number based on DNA content also showed no significant differences
among the groups, confirming that vibration did not adversely affect cell viability.
5.4.3. Vibration attenuates the expression of scleroderma phenotypic targets
To investigate the role of vibratory stimulation in modulating fibrotic gene
expression, the gene expression of scleroderma phenotypic targets were validated by
qRT-PCR. In 1X strain controls, mRNA levels of pro-inflammatory cytokines
(Interleukin 1 (IL1A), IL4, and IL6), lysyl oxidase (LOX), and tissue inhibitor of matrix
metalloproteinase 1 (TIMP1) were significantly elevated in SSc fibroblasts relative to
normal fibroblasts (Fig 5.3) In contrast, mRNA expression of Fli-1 proto-oncogene
(FLI1), a suppressor of collagen transcription, was significantly reduced in SSc
fibroblasts, while expression levels of fibrillin 1 (FBN1) were not significantly different.
Among samples cultured under vibratory conditions, expression levels of IL1A, IL4,
FBN1, and LOX were significantly lower in SSc fibroblasts relative to 1X strain controls,
while expression of IL6 and FLI1 was significantly increased.
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Figure 5.3. Vibration attenuates the mRNA expression of scleroderma phenotypic
markers on SSc fibroblasts. Relative mRNA expression levels of proinflammatory
cytokines (interleukin 1, alpha 1 (IL1A1), IL4, and IL6), matrix remodeling-associated
proteins including fibrillin-1 (FBN1), lysyl oxidase (LOX), and TIMP1), collagensuppressing transcription factors (FLI1) relative to static control at day 7. n = 4 samples
per group. *(P < 0.05) compared with normal dermal fibroblast group (Normal), †(P <
0.05) compared with 1X Strain group in each cell. All bar graphs, mean ± SD.
5.4.4. Vibration negatively regulates the mRNA induction of scleroderma phenotypic
targets by a fibrotic model in vitro
Cyclic strain was used as an in vitro fibrotic model to investigate the ability of
vibration to counteract a profibrotic stimulus. SSc fibroblasts seeded in porous
polyurethane sponges were exposed to one-time 15% cyclic tensioning (1X Strain), 1X
Strain followed by 5% cyclic strain alone (Cyclic Strain) or in combination with vibration
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(Cyclic Strain + Vibration). Samples cultured under cyclic strain alone exhibited
significant increases in profibrotic cytokines (TGFB1 and CTGF), the pro-inflammatory
cytokine (IL6), and FBN1 relative to the 1X Strain control.

Figure 5.4. Vibration negatively regulates cyclic strain-induced mRNA expression of
scleroderma phenotypic markers on SSc fibroblasts. Relative mRNA expression levels of
scleroderma (SSc) fibrotic targets including 1) profibrotic cytokines, 2) TGF-β signaling
moledules, 3) proinflammatory cytokines, and 4) key mediators involved in collagen
crosslinking and accumulation. All data were normalized to static control at 7 days. n = 4
samples per group. *(P < 0.05) compared with 1X Strain group, †(P < 0.05) compared
with cyclic strain group. All bar graphs, mean ± SD.
Samples exposed to Cyclic Strain + Vibration showed significant increases in the
mRNA expression of CTGF, EDN1, and IL6, but significant reductions in TGFBR2, IL4,
FBN1, LOX, and TIMP1 relative to the Cyclic Strain alone group and significant
reduction in IL1A relative to the 1X Strain control (Fig. 5.4). In addition, mRNA levels
for SMAD7, a signaling inhibitor involved in TGF-β signaling; and FLI1, a transcription
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mediator that negatively regulates collagen production by dermal fibroblast were
significantly increased compared with cyclic strain or 1X Strain groups.

Figure 5.5. Vibration inhibits cyclic strain-induced collagen synthesis and accumulation
and mechanical stiffening on SSc fibroblasts. Relative mRNA expression levels of
fibrous collagens normalized to static control at 7 days (A), collagen content, substrate
stiffness, and cell number (B). n = 4 samples per group. *(P < 0.05) compared with 1X
Strain group, †(P < 0.05) compared with cyclic strain group; ns, nonsignificant. All bar
graphs, mean ± SD.
5.4.5. Vibration inhibits cyclic strain-induced collagen synthesis and accumulation in Ssc
fibroblasts
In order to examine the effect of vibration on collagen gene transcription, protein
accumulation, and substrate stiffness, SSc fibroblasts seeded in porous polyurethane
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sponges were cultured under one-time tensioning strain, cyclic strain, and cyclic strain in
combination with vibration as described above. qRT-PCR results demonstrated that the
mRNA expression levels of COL1A1 in SSc fibroblasts exposed to cyclic strain alone
were significantly increased, although the difference was only statistically significant for
COL1A1 (Fig. 5.5A). In contrast, samples cultured under cyclic strain in combination
with vibration exhibited significant reductions in collagens COL1A1 and COL3A1
relative to both the cyclic strain and 1X strain control groups. In addition, cyclic strain
produced significant increases in collagen accumulation and substrate elastic modulus
relative to the 1X Strain control, while cyclic strain in combination with vibration
significantly decreased collagen deposition and elastic modulus relative to both the 1X
Strain and cyclic strain groups (Fig. 5.5B).
5.5. Discussion
Pathologic fibrosis can occur in every major organ, representing approximately
45% of all mortality worldwide [16,87,89]. Excessive deposition of extracellular matrix
(ECM) components, particularly collagens is generally regarded as a major outcome of
fibrotic diseases induced by a variety of stimuli including persistent scarring, chronic
exposure to infections and cytokines, autoimmune and allergic reactions, and radio- and
chemotherapy [151,392]. Myofibroblasts have long been regarded as a key effector cell
in fibrogenesis and primary effector cell responsible for synthesis of collagen and other
ECM components [77]. TGF-β, as the most important mediator is known to be upregulated and activated in a wide range of fibrotic disease and modulate myofibroblast
differentiation [24,143,393]. EDA-FN (extra domain A fibronectin) and mechanical
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tension are also important factors in the differentiation of mature myofibroblasts and
continuous exposure to these factors leads to increased stiffness of the fibrotic tissue and
ultimately organ failure [40,394].
Many studies have shown that fibroblasts derived from clinically affected fibrotic
lesions have altered mRNA expressions in cytokine and matrix-related genes that persist
even over extended periods in culture. Recently, manipulation of fibrotic phenotype in
myofibroblasts have gained considerable attention as a potential antifibrotic strategy.
Several studies suggest that the profibrogenic phenotype of myofibroblasts can be
controlled by substrate stiffness [111,165–168]. For example, Wang et al. demonstrated
that valvular myofibroblasts grown on soft substrates (~ 7 kPa, mimicking healthy
cardiac valve tissue) showed a decrease in α-smooth muscle actin (α-SMA) stress fibers
and proliferation and an increase in apoptosis, while the mRNA expression levels of αSMA and CTGF were significantly increased in valvular myofibroblasts cultured on stiff
substrates (~ 32 kPa, mimicking pre-calcified diseased tissue) compared with cells grown
on compliant substrates [165]. In addition, Goffin et al. reported that myofibroblasts
cultured on three-dimensional culture substrates with an increased stiffness exhibited
increased levels of α-SMA expression and induction of myofibroblast activation with
TGF-β1 supplementation, however, when fibroblasts cultured on the substrates with a
reduced tension corresponding to the compliance of normal connective tissue (e.g. skin),
no increases in the expression of α-SMA protein and collagen matrices were observed by
exogenous addition of TGF-β1 [395]. Moreover, Marinkovic et al. cultured IPF-derived
fibroblasts in collagen hydrogel substrates with the stiffness spanning from normal and
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fibrotic lung tissues [111]. They found that the contractile and proliferative function in
fibrotic fibroblasts were significantly inhibited when they were cultured in soft matrices
(~ 1 kPa of elastic modulus), approximating the physiological level of normal lung ECM
stiffness, suggesting that the myofibroblast phenotype is not a permanent state but can be
reversed by alterations in the matrix properties.
In addition to substrate stiffness, myofibroblast phenotype can be modulated by
externally-applied mechanical stimuli. Significantly decreased mRNA levels of α-SMA
and reduced cellular contractility were reported, when human peripapillary scleral
myofibroblasts were subjected to 1% cyclic strain compared to 4% cyclic strain applied
at 5 Hz [396,397]. The phenotypic conversion from myofibroblasts to fibroblasts can also
be obtained by the exposure to continuous static stretching as indicated by significant
decreases in collagen secretion and α-SMA mRNA expression [398–400]. Myofibroblast
subjected to cyclic strain (5%, 1 Hz) exhibited reduced mRNA expression of
myofibroblast markers (COL1A1, COL3A1, α-SMA, and TGF-β1) mediated by
decreased phosphorylation of SMAD2, which is a downstream effector in TGF-β
signaling [401]. Previously, we have shown that high frequency vibration down-regulated
TGF-β signaling and inhibited the induction of collagen synthesis and mechanical
stiffening in response to fibrotic stimuli. Here, using fibroblasts derived from both
clinically involved and uninvolved skin regions of patients with SSc, we tested whether
vibratory stimulation can reverse the profibrogenic phenotype in SSc fibroblasts.
A number of researchers have reported that SSc fibroblasts from clinically
affected skin are known to exhibit numerous phenotypic differences with expression of
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various cytokines and ECM components, particularly excessive expression of collagens
(COL1A1 and COL3A1) [402]. As a key effector of TGF-β, CTGF plays important roles
in the activation of SSc fibroblasts and promotes fibroblast proliferation and collagen
deposition synergistically with TGF-βs. It is noted that CTGF was consistently upregulated in the sclerotic lesion from patients with SSc [403]. In addition, CTGF mRNA
expression levels are increased approximately six-fold in the lesional fibroblasts relative
to nonlesional fibroblasts isolated from the same patients [404]. TGF-β receptor type 1
(TGFBR1) and TGFBR2 also exhibited a significantly increased expression in SSc
fibroblasts compared with normal fibroblasts from health donors [379,405], while the
mRNA levels of SMAD7, which is an endogenous inhibitor in TGF-β signaling, were
significantly down-regulated in SSc fibroblasts [380]. Pro-inflammatory cytokines (IL1
[368] and IL6 [370]) and matrix remodeling-related proteins (TIMP1 [374], LOX [376],
and FBN1 [406]) were significantly elevated in SSc fibroblasts from the affected lesion
compared with those from unaffected lesion, while significant increases in IL4 mRNA
levels in SSc fibroblasts were only investigated compared with normal fibroblasts [369].
In addition, the expression of FLI1 protein is consistently reduced in fibroblasts derived
from clinically involved scleroderma skin, which leads to enhanced collagen synthesis in
systemic sclerosis diseases [407,408].
We found that qRT-PCR results of lesional SSc fibroblasts versus nonlesional
SSc fibroblasts on TGF-β-related genes were consistent with previous observations
indicating differences in mRNA levels of major profibrogenic phenotypic targets in
fibroblasts derived from the clinically affected lesion of patients with SSc compared with

134

nonlesional or normal fibroblasts. The present study confirms that vibration downregulated TGF-β signaling through decreased expression of molecules involved in signal
transduction including SMAD3 and TGF-β receptors (TGFBR2 and TGFBR3) and
increased expression of molecules that are associated with signal inhibition (SMAD7,
SIK1, and SKIL) relative to 1X Strain controls, demonstrating that vibration can still be
effective in modulating the TGF-β responsiveness of fibrotic fibroblasts. Interestingly,
significant increases in profibrotic cytokines (TGF-β, CTGF, and EDN1) were observed
in response to vibration. In accordance with previous studies, it is widely reported that
externally-applied mechanical stimulation induced increased expression of profibrotic
cytokines and altered matrix synthesis and degradation [245,322,337,338,409,410].
Specifically, the expression of profibrotic cytokines such as TGFB1 and CTGF is
mechanoresponsive and significantly increased in response to various mechanical
stimulation by a number of cell and tissue types including lung fibroblasts [245,409],
periodontal ligament fibroblast-like cell (PDL) [410], gingival fibroblasts [337],
laryngeal fibroblasts [338], and tracheal fibroblast [322] compared to nonloaded
condition. An increased expression of profibrotic cytokines by mechanical stimulation
was known to promote collagen synthesis and accumulation. However, vibration
significantly reduced collagen mRNA expression and synthesis, as well as mechanical
stiffening of the substrates induced by cyclic strain through the down-regulation of TGFβ signaling.
In addition to alternations in TGF-β and collagen expression, fibroblasts derived
from SSc lesional biopsies also exhibited alterations in a number of other targets
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including inflammatory cytokines and molecules involved in matrix assembly,
crosslinking, and stability in response to vibration. Our findings suggest that vibratory
stimulation induced differential expression of the pro-fibrogenic markers through reduced
expression of TGF-β receptor type 2 (TGFBR2), pro-inflammatory cytokines (IL1A and
IL4), and matrix remodeling-associated molecules (FBN1, LOX, and TIMP1) and
increased expression of SMAD7, an inhibitor in TGF-β signaling and FLI1, a suppressor
of collagen transcription. Although many of profibrogenic phenotypic targets were
activated in SSc fibroblasts as previous reported [92], vibration was able to positively
control the pathologic markers of SSc fibroblasts.
Many studies suggest that mechanical stimuli including substrate stiffness and
externally-applied mechanical forces play an important role in regulating the fibrotic
phenotype and matrix expression [41,396–399]. As an in vitro fibrotic model, cyclic
strain is a known profibrotic stimulus that promotes increased collagen deposition via a
TGF-β-dependent mechanism [228,232,244]. When SSc fibroblasts were subjected to
cyclic strain in combination with vibration, profibrogenic phenotype markers including
molecules involved in collagen crosslinking processes (TGFBR2, IL4, FBN1, LOX, and
TIMP1) were significantly decreased, while anti-fibrotic molecules (SMAD7 and FLI1, a
collagen synthesis inhibitor) were significantly increased. Moreover, vibration exhibited
significant reduction in COL1A1 mRNA levels induced by cyclic strain alone.
Furthermore, strong induction in collagen content and increases in mechanical stiffening
were significantly reduced in response to Cyclic Strain + Vibration relative to cyclic
strain or 1X Strain control. These studies, therefore, suggest that profibrogenic phenotype
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of scleroderma fibroblasts could be reversed by vibratory stimulation. Mechanical
stimulation serves as an important mediator in the context of matrix remodeling,
particularly collagen synthesis and degradation. As a novel antifibrotic mechanotherapy,
vibration may offer several benefits relative to current anti-TGF-β strategies: 1) it can be
easily and locally applied and 2) no systemic side effects can be triggered compared with
systemically-administered pharmacological approaches. A limitation of present study was
that scleroderma fibroblasts subjected to cyclic strain along with ascorbate
supplementation were used as an in vitro fibrogenic model. However, fibrosis is a highly
complex, dynamic disease and cannot be perfectly emulated in vitro. In addition, while
we have mainly focused SSc fibroblasts as a key effector cell in fibrosis, it is important to
acknowledge that a variety of inflammatory cells are involved in the fibrotic pathogenesis
and the role of vibration on pro-inflammatory cytokines needs to be established in the
future studies. In order to address this issue, the reversibility of profibrogenic phenotype
mediated by vibratory stimulation will be further demonstrated in animal models with
dermal fibrosis induced by gamma irradiation [411] or bleomycin [412].
5.6. Conclusion
This study is the first to show that high frequency vibration was able to reverse
the profibrotic phenotype of SSc dermal fibroblasts by down-regulating TGF-β signaling,
decreasing collagenous matrix remodeling-related genes (FBN1, LOX, and TIMP1), and
increasing collagen transcriptional suppressors (FLI1). Moreover, vibration reduced the
mRNA and protein expression of collagens COL1A1 and COL3A1 and decreased
mechanical stiffness of polyurethane sponges seeded with SSc dermal fibroblasts,
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suggesting that the myofibroblastic activation of SSc dermal fibroblasts could be reversed
by vibration. Hence, vibration-mediated therapy could be used as a clinical approach for
the treatment of a wide range of fibrotic diseases.
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CHAPTER SIX
CONCLUSIONS AND FUTURE RECOMMENDATIONS
6.1. Conclusions
The overall goal of this dissertation was to investigate the roles of vibratory
stimulation in the matrix remodeling in the superficial lamina propria of vocal folds and
demonstrate the potential of vibratory stimulation for treatment of fibrotic diseases.
Pharmaceutical approaches targeting particularly TGF-β and its downstream molecules
have been regarded as promising strategies, however, no clinical treatments have
successfully demonstrated their therapeutic effects against a wide ranges of fibrotic
diseases. A small number of recent studies have shown that alteration of the mechanical
microenvironment can alter matrix remodeling and reverse the pathogenic phenotype of
myofibroblasts into quiescent fibroblasts. While these results are encouraging, their
translational therapeutic application is challenging.
The present studies demonstrate for the first time the ability of externally applied
mechanical stimulation in the form of high frequency vibration to inhibit fibrotic
signaling, block increases in collagen and substrate stiffness in response to profibrotic
stimuli, and reverse the fibrotic phenotype of fibroblasts derived from pathological tissue.
It appears that the major mechanism is the ability of vibration to modulate the expression
of a wide range of gene targets involved in TGF-β signaling, with the net result of
reducing signaling capacity. However, these studies also demonstrate potential for
accelerating catabolic remodeling of collagenous matrix, indicating that vibration may
work through multiple mechanisms. The studies of gene expression in response to
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variable vibratory stimulation demonstrate that while fibroblasts do exhibit dose and
temporally-dependent responses to vibration, many key targets such as HAS enzymes and
collagens respond similarly to a wide range of vibratory regimes, demonstrating the
robustness of this response. The observation that the changes in gene expression induced
by vibration are almost entirely reversed within 18 hours after removal of vibration
indicates that these are transient responses and that whatever final form vibratory
mechanotherapy may take, it will need to be designed in manner suitable for repeated
application. While these studies most strongly support the ability of vibration to inhibit
the initiation of fibrotic responses, studies demonstrating the capability of vibration to
promote turnover of previously synthesized matrix and alter expression of proinflammatory genes suggest that vibration may also have potential to therapeutically
intervene at least in the early stages of disease progression.
6.2. Recommendations
The vibratory bioreactor used in these studies has been successfully manufactured
and used as described previously [231,322,325,365]. However, there are experimental
limitations that our vibratory module can only produce the frequency range from
approximately 25 to 150 Hz [413–416], which is close to the fundamental frequency
range in men’s voice. In future studies, the vibratory bioreactor that can provide more
broad range of frequency that corresponds to physiological levels (100-300 Hz) including
the fundamental frequency ranges of men and women will be needed to fully understand
the ECM regulation mechanism in response to vibration.
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Moreover, numerous studies have demonstrated the crucial role of several
fibrogenic cytokines released from macrophage and immunocytes in a variety of fibrotic
diseases [53,87,417,418]. Thus, it is important to acknowledge that a variety of
inflammatory cells are involved in fibrotic pathogenesis and the role of vibration on the
expression of pro-inflammatory and anti-inflammatory cytokines needs to be established
in the future studies. As a first step, fibroblast/macrophage co-culture system would be an
appropriate model to investigate the effects of vibration on the key inflammatory
components that are associated with fibrotic diseases.
Another important limitation of this research is that we have primarily focused on
fibroblasts as the key effector cell of fibrotic diseases. However, fibrosis is a highly
complex, dynamic, multicellular as well as progressive autoimmune disease that affects
all major internal organs and eventually leads to organ dysfunction and failure [419]. Our
in vitro models created by either exogenous addition of TGF-β1 or cyclic strain along
with ascorbate supplementation cannot fully replicate the fibrosis model. The therapeutic
efficacy of vibration, therefore, will be further demonstrated in the future studies using
animal models with dermal fibrosis induced by gamma irradiation [411] or bleomycin
[412].
However, a major challenge for the proposed in vivo studies is that our bioreactor
module could not apply to the animal models due to its operational complexity and nonportability. Therefore, it will be necessary to design a small flexible, portable device
suitable for delivering vibratory stimulation to test clinical efficacy of vibratory
stimulation in animal models with fibrotic diseases. It is also essential to acknowledge
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that SSc, keloids, and hypertrophic scars in the skin are the most readily accessible
targets, however, substantial innovation and engineering design will be required for
application to non-superficial tissues such as lung, liver, kidney, and heart. As an
emerging technology, polymeric actuators are recently being investigated as a promising
technology in biomedical applications such as microsensors and artificial muscles, owing
to their flexibility, lightweight, performance, and ease of fabrication [420–424].
Specifically, the research conducted by Kim et al., showed that polymeric electroactive
actuator composed of sulphonated block copolymers and ionic liquids produced a fast
and robust millimeter-scale displacement at low voltages [425], suggesting a potential
intervention that may be employed in the future studies. However, more thorough
consideration in development of the vibration-producing devices will be required to
achieve our long-term goal.
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